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FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
and Trust Chief Executives (HATCH) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterTASC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
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SUMMARY 
 
What is the expected burden of major depression? 
 
Depression remains a significant burden on society as a whole and is one of the most 
common reasons for consulting a general practitioner.  
 
Accepting previous UK estimates of annual consultation rates by patients with major 
depression of about 6%, around 30,000 diagnosed depressed patients per annum would be 
expected to be seen, in the primary care sector, for a 'typical' health authority population of 
500,000. 
 
Up to 25% of people suffering depression will not present to primary healthcare services, 
and of those who do only approximately 50% will be diagnosed accurately on their initial 
visit. Therefore, the true burden of depression within the community is likely to be much 
higher than that actually recognised in general practice. 
 
What are the current levels of SSRI prescribing?  
 
The volume of antidepressant prescribing generally has increased over the last decade, with 
substantial growth in the use of drugs such as selective serotonin re-uptake inhibitors 
(SSRI)s and heterocyclics. Overall, prescribing rates are now similar between SSRIs and 
tricyclic antidepressants (TCA)s with 47% of the total prescribing volume attributable to 
SSRIs. In cost terms, SSRIs are now estimated to account for over 85% of the total NHS 
antidepressant budget, currently estimated at approximately £214 million per year. 
 
Recent analysis of UK patterns of prescribing for antidepressants in general practice  
reveals that TCAs remain commonly (60-70%) prescribed at dosages below the theoretical 
therapeutic levels, and this remains unexplained by legitimate periods of simple dosage 
titration. This sub-therapeutic dosaging issue is not generally seen with SSRIs, or newer 
TCA-related drugs.  
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Do SSRIs have a greater clinical efficacy than TCAs? 
 
There exists a large body of well over 100 randomised controlled trials (RCT)s which have 
made direct comparisons of efficacy and clinical effectiveness between SSRIs and TCAs. 
However, these trials are dominated by small studies conducted within the secondary care 
setting over clinically short periods of time (6-12 weeks), thus, limiting their individual power 
and generalisability. Trials also vary in terms of the TCA type used as a comparator (i.e. 
older TCA, newer TCA or heterocyclic). Also the precise dosing of the comparator drug and 
the SSRI can vary enormously. This heterogeneity across the trial evidence base limits 
individual trial power and overall generalisability. 
 
There are now several formal meta-analyses which suggest that, despite small effect 
advantage in favour of TCAs, there are no significant clinical differences between SSRIs 
and TCAs. 
 
Are SSRIs better tolerated than TCAs? 
 
The meta-analyses have commonly used both overall and adverse effect related drop-out 
rates from RCTs as proxies for treatment tolerability. On an individual RCT trial basis there 
remains great variation in both study design and patient group leading to similar differences 
in findings for drop-outs. The general conclusions are that SSRIs and related drugs are 
generally better tolerated than the older TCAs and that treatment withdrawals, due to 
adverse effects, are less common when using SSRIs than TCAs.  
 
The overall drop-out rate for TCA-related drugs is commonly reported at levels of around 
30-35% (or 14-19% when limited to drop-outs related to adverse effects only). The typical 
absolute difference in overall ‘all-cause’ drop-out rates appears to be approximately 4-5%, in 
absolute terms, in favour of SSRIs.  
 
Current evidence suggests that observed differences between SSRIs and TCAs, in terms of 
overall and adverse effect related drop-out rates, only reach statistical significance when 
considering the older TCAs (commonly associated with poorer adverse effect profiles). This 
point has a big impact in terms of an appropriate choice of reference TCA drugs.  
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Do patients taking SSRIs have a reduced likelihood of overdose or suicide? 
 
Although there is a strong theoretical argument that a move towards the wider use of first-
line SSRIs could reduce levels of suicide and associated costs, there remains no clear 
evidence of any economic advantage. It is also debatable as to whether a real reduction is 
possible, or whether it would simply shift the balance in the methods of suicide. This is an 
area which requires more research, and is likely to require a modelling approach due to the 
very low observed event frequency.   
 
Are SSRIs more cost-effective in treating major depression than TCAs? 
 
The relative cost-effectiveness and economic case for the first-line use of newer SSRI drugs 
have been considered by a number of studies and have generated much debate. The 
majority of these studies have been based on either clinical decision models or on 
retrospective analysis of patient records. Whilst earlier economic studies tended to support 
an economic advantage with SSRIs, a number of later modelling studies have challenged 
this view. The most contentious modelling issue relates to the interpretation of drop-out data 
drawn from previous RCTs, meta-analyses and/or expert-panels.  
 
There remains only one naturalistic randomised study of SSRIs and TCAs, which appears to 
suggest that, in a clinically realistic environment, where switching treatment is allowed, there 
is no clear evidence of a cost-effectiveness advantage for the general first-line use of 
SSRIs. Therefore, as yet, there appears to be no clear economic evidence which can 
support the use of first-line SSRIs for all patients. 
 
Are SSRIs more expensive than TCAs? 
 
The cost of SSRIs is currently around 5-6 times that of standard TCA drugs, such as 
amitriptyline and dothiepin. Newer TCA-related drugs, including lofepramine, although more 
expensive than older TCAs, also remain significantly cheaper than SSRIs (at around 25% of 
average SSRI costs).  
 
However, generic versions of fluoxetine (Prozac - expected in early 2000) will almost 
certainly drive down the costs of all SSRIs and it would seem unlikely that such scales of 
increased costs of SSRIs will persist. In the light of the existing data on both cost-
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effectiveness and patient drug tolerance, a lower drug cost for SSRIs is likely to lead to a 
much more favourable and clearer cost-effectiveness argument in favour of SSRIs.  
 
What other new evidence on SSRIs should we expect? 
 
An ongoing HTA randomised study is likely to provide further UK-based evidence of the role 
of first-line SSRIs in the treatment of depression; however, this is not expected to report until 
at least the year 2002. 
 
There remain two ongoing meta-analyses, conducted as part of the Cochrane collaboration, 
which should provide health professionals with regular up-dated considerations of the 
evidence related to the first-line use of SSRIs, in terms of both efficacy and patient tolerance 
of treatment. 
 
On the basis of the current evidence, the key messages for purchasers are: 
 
 To formulate local guidelines on the diagnosis and management of depression. 
 
 That further work is required specifically to answer the question of the cost-effectiveness 
of SSRIs compared with newer TCAs. 
 
 To consider the use of the newer TCA lofepramine - unless contraindicated as a first line 
drug choice. 
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ABBREVIATIONS 
 
  
CCOHTA Canadian co-ordinating office for health technology assessment 
CEA Cost-effectiveness analysis combining cost and health benefits   
CER Cost-effectiveness Ratio 
CUA  Cost utility analysis combining cost and benefits weighted for patient 
preference 
GPRD General Practice Research Database 
HCA Heterocyclic antidepressant 
HDRS Hamilton Depression Rating Scale 
HMO Health Maintenance Organisation 
MAIO Monoamine oxadase inhibitor 
MAOI Monoamine oxidose Inhibitors 
NNT Number needed to treat 
ONS Office of National Statistics 
OPCS Office of Population Censues and Survey 
OR Odds ratio 
PPA Prescriptions pricing authority 
QALY Quality adjusted life year 
RCT Randomised controlled trial 
RIMA Reversible inhibitor monoamine oxadase 
RR Relative Risk 
SSRI Selective serotonin re-uptake inhibitor 
TCA Tricyclic antidepressant 
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1. INTRODUCTORY REMARKS  
 
Depression is widely recognised as a significant burden on health services and society as a 
whole, and can result in significant levels of suffering for both patients and families alike.
1
 It 
is estimated that around two thirds of adults will, at some time in their lives, experience 
depression or worry of sufficient severity to influence their daily activities.
2
 For the majority of 
people, episodes of depression are relatively short-lived, but a minority experience a range 
of severe psychological and physical symptoms.  
 
Depression remains one of the most common reasons for consulting a general practitioner, 
and the majority of depressed people who receive treatment do so within a primary care 
setting. Despite the impact of national campaigns to heighten the general awareness of 
depression as a serious health issue,
3,4,5
 it is widely accepted that clinical depression 
remains under-treated in many cases. Almost a half of all cases of major depression remain 
unrecognised on initial presentation to primary care health services; with patients often 
presenting with non-specific ‘physical’ symptoms related to their underlying mental illness.
2
 
 
The discovery of antidepressants has undoubtedly shifted the balance of treatment more 
towards drug-based therapy. The development of less toxic and better tolerated novel 
drugs, such as selective serotonin re-uptake inhibitors (SSRI)s, has further accelerated the 
use of pharmacology in the management of depression, leading to considerable interest in 
their relative efficiency and effectiveness in the treatment of depressive illness. As a result, 
the proportion of patients prescribed SSRIs for depression has increased dramatically, 
bringing with it an overall increase in the drug bill for antidepressants.
6
 
 
The SSRIs remain relatively expensive drugs, when compared to alternative tricyclic 
antidepressant (TCA) drug therapy, with prescribing data suggesting costs of up to 5-6 
times those of conventional TCAs. Their increased use as a first-line treatment, therefore, 
poses a real challenge to existing and future drug budgets.
7
 
 
There are now well over 100 recognised randomised controlled trials (RCT)s which have 
compared SSRI drugs with either older tricyclic antidepressants or newer TCA-related 
heterocyclic antidepressants (HCA)s. However, despite this considerable research effort, 
there appears little consensus as to which class of drug should be given as first-line 
treatment in depression.  
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The purpose of this Guidance Note is to bring together an overall picture of the current 
evidence, views and guidelines related to the first-line use of SSRIs.  
 
The report considers two key research issues: 
 
1. What is the quantity/quality of evidence regarding the significant difference in clinical 
efficacy/effectiveness between SSRIs and TCAs/TCA-related drugs (both in randomised 
studies and natural clinical settings)? 
 
2. Is there any evidence to suggest a clear advantage between antidepressant treatments 
in terms of their value for money? 
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2. DESCRIPTION OF UNDERLYING DISEASE   
 
The importance of improving identification, diagnosis and the appropriate treatment of 
people with depression has long been recognised. The Diagnostic and Statistical Manual of 
Mental Disorders – Fourth Edition (DSM-IV) criteria for major depression defines that a 
patient must have had symptoms for a period of at least two weeks, including at least five of 
the following symptom types:
8
 
 
 depressed mood  weight loss/gain 
 loss of interest/pleasure  insomnia or hypersomnia 
 psychomotor agitation/retardation  fatigue/loss of energy 
 feelings of worthlessness/excessive guilt  suicidal thoughts 
 impaired thinking/indecisiveness  
 
The criteria specify that the first two of these symptoms (i.e. a depressed mood and loss of 
interest) must be present for a diagnosis of major depression. Similar criteria for diagnosis 
exist within the International Classification of Diseases (ICD-10) diagnosis coding.
9
 
 
Depression often results in a long-term chronic illness, with relapses commonplace and 
cyclical patterns of disease the norm for many patients. The historical social stigma, that 
past generations have placed on mental illness, also compounds this problem with many 
sufferers failing to present to the health services. Previous estimates of the rate of non-
presentation suggest that anywhere between 25-50% of people suffering depression will not 
visit their GP. It is also difficult to estimate accurately the true rates of successful diagnosis 
of depressed patients who present to GPs. However, it is widely believed that GPs will only 
diagnose correctly 40-50% of presenting cases at an initial consultation. Therefore, despite 
the existence of recognised and accepted common diagnostic criteria, the estimation of both 
incidence and prevalence for major depression remains extremely problematic; complicated 
further by the diverse nature of depressive illnesses themselves. It is likely, therefore, that 
what is seen as formally diagnosed depression represents only a fraction of the true burden 
of illness in the community.  
 
Examples of previously published estimates of prevalence rates for major depression are 
shown in Table 1. Analysis of data on general practice consultations suggests an annual 
consultation rate of individuals with diagnosed depression of between 5-6%, with an 
expected 2-3 consultations per patient.
10,11
 The Office of Population Censuses and  Surveys 
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(OPCS) survey of Psychiatric Morbidity estimated that 2-3% of the adult population 
experienced a depressive episode during the previous week of the survey (or 9-10% if the 
wider diagnostic category of depressive episode or mixed anxiety and depressive disorder 
was adopted).
12
 
 
Table 1 Estimates of Prevalence of Major Depression 
Source Consultation Rate of Patients / Prevalence 
Key National Survey Data  
1. 1
. 
Key Health Statistics from General Practice 1996
11
 
General Practice Research Database (GPRD) – annual 
figures  
(ICD 9 : 298,300,311 + drug prescribing 4.1-4.3 BNF) 
• 59.1 per 1,000 patients 
• 5.9% per annum consultation rate 
• 8.2% female / 3.6% male 
2. 2
. 
Morbidity Statistics in General Practice, 1991
10
  
Annual figures from GP electronic records  
(ICD 9 298,300,311 as in Key Statistics) 
• 45.8 per 1,000 patients  
• 99.6 consultations per 1,000 patients 
• 4.6% per annum consultation rate 
3. 3
. 
OPCS Surveys of Psychiatric Morbidity in Great Britain
12
 
Report 1 : The prevalence of psychiatric morbidity among 
adults living in private households 
1 week prevalence survey  
• Depressive episode: 2.1% in last week 
• Depressive episode + Mixed anxiety & 
depressive disorder: 9 - 10 % in last week 
4. 4
. 
Health of the Nation - Key Area Handbook - Mental Health  • Depressive disorders:  2%-5%                    
(precise time period unclear) 
• Affective psychosis 0.1%-0.5% 
 
 
Accepting the Key Health Statistics from General Practice (1996) figures as a reasonably 
representative and reliable estimate of a national annual consultation rate for depression, 
(i.e. 5.9% per annum.), then the primary care sector, for a 'typical' health authority 
(population 500,000) might expect to see around 30,000 diagnosed depressed patients per 
annum.  
 
Episodes of major depression are reported to be around twice as common amongst women 
as men, rising steadily with age, and are strongly associated with adverse social and 
economic circumstances such as unemployment, divorce or separation, inadequate housing 
and lower social class.
2
 A national age/sex break down of the prevalence of treated 
depression is shown in Figure 1; it is taken from the Key Health Statistics from General 
Practice, 1996. The data are summed to a crude overall rate, which is further adjusted to 
reflect the national age/sex mix. 
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Figure 1 Consultation Rates (persons) for Treated Depression per 1,000 
Population per Annum 
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3. CURRENT SERVICE PROVISION  
 
3.1 PROFILE OF CURRENTLY PRESCRIBED ANTIDEPRESSANTS 
 
The current treatment for major depression is very much focused on the delivery of health 
care services through the primary care network. As such, it is general practitioners, practice 
nurses and community mental health professionals who play the major role in both the 
identification and diagnosis of depressive illness and the delivery of clinically effective 
treatments.  
 
Drug-based therapy using antidepressants (see Table 2) remains the main treatment mode 
for depression within the UK, with an estimated one million person-years of treatment 
provided annually.
7
 There are five main sub-groups of antidepressant: the older ‘first-
generation’ TCAs; newer ‘second-generation’ TCAs; TCA-related drugs (heterocyclics); 
monoamine-oxadase inhibitors (MAOIs); and SSRIs (including related drugs).
13,14
 
 
First-generation TCAs were first introduced in 1959 and have remained, to date, the most 
frequently used group of antidepressant drugs. Newer TCAs and TCA-related drugs have 
been developed subsequently; they tend to be generally less toxic and different in their side-
effect profile in comparison with the older TCAs. TCAs act by blocking re-uptake of the 
neurotransmitters serotonin and noradrenalin. 
 
The SSRIs, as a drug class, are far more targeted in their mechanism of action of blocking 
serotonin (5-HT). With reduced adverse-effect profiles, they are generally found to be less 
sedative and are viewed as ‘safer’ in terms of their impacts on patient life-style (for example, 
driving and the use of machinery). SSRIs cause minimal anticholinergic or psychomotor 
side-effects, lack cardiotoxicity and their use does not lead to the weight gain commonly 
associated with TCAs. The risk of toxicity in overdose is also greatly reduced.
15
 
 
MAOIs tend to have a number of associated dietary and drug interaction restrictions. Their 
use can also influence the subsequent use of other antidepressant groups (TCAs and 
SSRIs). As such, there is a general recommendation that a 1-2 week antidepressant-free 
period is observed when switching either from, or to, a MAOI-based therapy. A sub-class of 
these drugs is based on reversible inhibition of monoamine oxidase (RIMA)s. These drugs 
carry slightly less risk of interaction, but diet and drug restrictions still apply. In relative 
terms, the MAOI and RIMA drugs represent a very limited share of the antidepressant 
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market and are commonly reserved for use in drug-resistant patients or those with specific 
phobic forms of depression; thus, they are not considered as a potential option for first-line 
treatment. 
 
Table 2  Currently Prescribed Antidepressant Drugs in the UK 
 
Class Drug Market Share %  
(Prescription Numbers) 
  Within Class Overall 
TCAs (older) Amitriptyline  38.5%  18.7% 
 " Imipramine  5.1%  2.5% 
TCAs (newer) Dothipen  42.2%  20.5% 
 " Doxepin  2.1%  1.0% 
 " Desipramine  0.1%  0.0% 
 " Trimipramine  3.5%  1.7% 
 " Amoxapine  0.1%  0.1% 
 " Clomipramine  6.4%  3.1% 
 " Nortriptyline  1.9%  0.9% 
 " Protriptyline   0.1%  0.1% 
 " Viloxazine  0.0%  0.0% 
 " Mirtazapine  0.1%  0.0% 
Total Market Share   100%  49% 
TCA-related (heterocyclics) Lofepramine  67.6%  6.9% 
 Maprotiline  1.6%  0.2% 
 " Mianserin  6.4%  0.7% 
 " Trazodone   24.5%  2.5% 
Total Market Share   100%  8% 
MAOIs Phenelzine  31.1%  0.3% 
 " Isocarboxazid  5.7%  0.1% 
 " Tranylcypromine  32.5%  0.3% 
RIMA Moclobemide  30.7%  0.3% 
Total Market Share   100%  1% 
SSRIs & Related Fluoxetine  43.2%  23.3% 
 " Fluvoxamine  0.9%  0.5% 
 " Paroxetine  32.6%  17.6% 
 " Sertraline  12.9%  6.9% 
 " Citalopram  3.8%  2.0% 
 " Nefrazodone  1.4%  0.8% 
 " Venlafaxine  5.2%  2.8% 
Total Market Share   100%  43% 
Source : Mediplus data,1996 
 
Therefore, the real choice faced by a GP wanting to use antidepressant drugs to treat a 
patient with an initial episode of depression, lies between an SSRI or a TCA (either 
conventional or a more recent related drug). Table 2 lists the current UK prescribed 
antidepressant drugs and indicates the market share of each drug, both within class and 
across all antidepressants, based on an analysis of 1997 prescribing data for England. 
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Despite the fact that most antidepressants have comparative clinical efficacy when 
prescribed optimally, a significant number of patients do drop-out of treatment and patients 
can experience relapse following initial treatment success.
16
 The level of drop-outs and 
relapses can be related, at least in part, to the tolerability of the drug (in terms of its adverse 
event profile) and the overall clinical efficacy of the drug. 
 
3.2 KEY THEMES OF ANTIDEPRESSANT PRESCRIBING 
 
The Defeat Depression Campaign has greatly influenced the management of depression 
within the UK in recent years.
5
  This campaign was organised by the Royal Colleges of 
General Practitioners and Psychiatrists and formulated an overall consensus of opinion as 
to the best practice in treating depressed patients. The emerging themes from the study are 
summarised below: 
 
 optimum therapeutic dosage; 
 adequate continuation of prescribing; 
 compliance with drug therapy. 
 
Although an accurate diagnostic process is the first step in providing good coverage of 
health services for depression, in itself it does not ensure effective treatment.  The 
prescribed dosages of antidepressants are often much lower than those suggested in 
clinical guidelines, possibly due to the reluctance of GPs to expose patients to unpleasant 
side-effects or inadequate reviews of therapeutic levels. 
 
As a rule, patients remain far more likely to receive an adequate therapeutic dose of an 
SSRI than a TCA.
17
 Donoghue et al. analysed national prescribing data using both 
Prescription Pricing Authority (PPA) data, and a general practice data (DIN-LINK) covering 
the records of over 750,000 patients.
18,19
 These studies both suggest that whilst over 95% of 
prescribing of SSRIs is achieved at therapeutic dosage levels, this is certainly not the case 
with the older TCAs (estimated to be prescribed at therapeutic dosages in only 10-15% of 
cases). The results were close between both databases, despite the fact that only the DIN-
LINK data allowed prescribing volumes to be restricted to diagnostic codes for major 
depression.  
 
As a result, TCAs are often given at such low levels that adverse events are unlikely to 
occur, but this also restricts the therapeutic impact of the treatment. There appeared to be 
only a small temporal change in the levels of sub-therapeutic prescribing of TCAs, when 
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these data were considered for both 1993 and 1995. Overall, the proportion of all 
prescriptions for antidepressants at sub-therapeutic dosages decreased from 60% to 47%, 
but this was almost entirely due to the increased market share of SSRIs (21% to 35%) over 
the same period of time. The issue of actual prescribing dosage being less than used in 
RCTs, and hence that adopted in guidelines, will have a significant impact on the actual 
clinical effectiveness and hence overall cost-effectiveness of treatment. 
 
Adequate continuation of prescribing is also of major importance. To prevent relapse, a four 
to six month continuation or maintenance phase is recommended after initial 
recovery/response to episodic treatment.
5
 It is even suggested that, for patients with a 
history of relapse, longer-term maintenance of up to two years should be considered. 
Unfortunately, an estimated 40% of patients only receive medication for up to a maximum of 
three months irrespective of the specific type of antidepressant medication. As a result, 
relapse remains a serious problem and around half of patients, whose symptoms have 
initially resolved successfully, experience relapse within a year of discontinuing the drug 
treatment. 
 
Patient compliance (or adherence) is another influential aspect of prescribing that will impact 
on a treatment's overall effectiveness. Adherence to treatment is a complex issue and will 
be related not only to the adverse effects of a treatment (or tolerability), and the clinical 
efficacy of the treatment, but also to socio-demographic factors.  
 
Therefore, a theoretically optimal antidepressant therapy is one which can be prescribed 
consistently at a therapeutic dosage, for adequate periods of time after resolution of the 
depressive episode, whilst maximising patient adherence through minimised adverse 
events. 
 
3.3 PRESCRIBING PATTERNS FOR ANTIDEPRESSANTS 
 
A recent study by Mason et al.
6
 looked at the prescribing patterns of antidepressants in 
England over the period 1991 to 1997. The primary aim of this analysis was to attempt to 
assess the impact of previous antidepressant prescribing advice, as provided by the 
Effective Health Care Bulletin, which was distributed to all health authorities and GPs in 
England and Wales in 1993.
2
 The total quantity and cost of primary care prescribing of 
antidepressants was derived from data obtained from the PPA, reflecting the total number of 
prescriptions reimbursed on a quarterly basis. Because prescriptions may not accurately 
describe the true volume of drugs used, in terms of patient treatment, the authors adjusted 
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the quantity data using the World Health Organisation’s tables of defined daily doses. This 
provided the volume of antidepressants used, calculated in person year equivalents. 
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Figure 2 Volume of Antidepressants used in England (shown quarterly in 
person-year equivalents) 
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Source : Mason et al. (1998/99), Health Trends, Vol 30, No 4 ,1998/9. 
 
In the first quarter of 1991, GPs were prescribing less than 7,000 person years of SSRI 
treatment. At the same time, the volume of prescribed TCAs was just under 129,000 person 
years. However, between 1991 and 1997 the volume of SSRIs prescribed increased 
substantially. Prescribing rates rapidly approached the higher volume of TCAs and soon 
after the end of the period of monitoring prescribing levels of SSRIs overtook those of TCAs 
(see Figure 2). In the first quarter of 1997, GPs were prescribing in total over 330,000 
patient years of antidepressant treatment (equivalent to treating 2.4% of the population), 
with 47% of the total prescribing volume due to SSRIs.  
 
A similar study of GPs' perceptions of antidepressants by Martin et al. examined the number 
of inceptions (beginning of a course of treatment) and discontinuations of antidepressants in 
general practice.
20
 The study collected a total of 4,000 GP weeks of recording per year, 
between July 1990 and June 1995. Overall, antidepressant inceptions rose by 116% 
between 1990 and 1995. However, over the same period, SSRI inceptions increased by an 
exceptional 732%. 
 
3.4 CURRENT SERVICE COSTS 
 
Previous estimates of the direct UK health costs of treating depression range between £222 
million and £420 million a year, and include both drug and non-drug costs.
1,21
 In fact, such 
studies have typically suggested that the cost of antidepressants accounts for only 15-20% 
of such cost burden of illness estimates.  
 17 
 
 
 
 
 
However, as previously highlighted, more recent analysis shows dramatic increases in the 
prescribing of SSRIs over recent years, with an almost equal volume of market share 
between SSRIs and TCAs now clearly evident.
6
 Levels of SSRI prescribing are judged to 
account for over 85% of the total NHS antidepressant cost, with the annual NHS drug costs 
for all antidepressants, as of the last quarter of data, estimated at £214 million per year.  
Previous guidelines have estimated annual NHS antidepressant expenditure at £160 million, 
therefore, it is clear that the overall costs of antidepressant prescribing are increasing 
rapidly year on year.
7
 To date, the NHS cost of SSRIs is 5-6-times that of conventional 
TCAs, and remains higher than that of newer-TCAs (see Table 3). 
 
 
Table 3 Average per Patient Cost of 28 Days' Treatment at WHO Defined Daily 
Dose 
Antidepressant Sub-Group  Cost (£), March 1996 
Average older TCA £3.93 
Lofepramine £7.73 
Average SSRI £21.74 
SSRI-related £35.47 
RIMA £19.01 
Average Antidepressant £11.31 
Source : North of England Guidelines 
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4. METHODS  
 
The aim of this evidence-based literature search strategy was to identify existing published 
reviews and meta-analyses which have considered a comparison of efficacy, clinical-
effectiveness or cost-effectiveness between at least one SSRI antidepressant and a 
recognised TCA or TCA-related alternative antidepressant. Given the prior knowledge of the 
existence of a number of key relevant meta-analyses, the authors did not attempt to re-
identify all original randomised double-blinded controlled clinical trials of SSRIs versus either 
placebo or TCA/related drugs, as they felt that the published data provided a sufficient 
evidence-based review already. 
 
As such, the search strategy was focused on a review of the following mainstream health 
related electronic databases, covering the period January 1990 - June 1999: MEDLINE;  
EmBASE; PsychLit. 
 
As well as focusing on these key reference databases, the authors also reference abstracts 
held on the Cochrane systematic review database and the NEEDS/DARE databases held at 
the NHS Centre for Reviews and Dissemination, again using the same general search 
terms. 
 
In conducting the search, combinations of terms were used which related to: 
 
 serotonin-uptake-inhibitors/all subheadings; 
 antidepressive-agents, trycyclic/all subheadings; 
 meta-analysis; 
 review-literature/all subheadings. 
 
In order to ensure coverage of pharmacoeconomic studies of antidepressants published 
since the publication of the identified economic reviews, a supplementary literature search 
was conducted based on the electronic databases MEDLINE, Psychlit and EmBASE 
covering the period January 1998 to March 1999. The authors looked specifically for studies 
related to the search term  ‘costs-and-cost-analysis/all subheadings’, in combination with the 
earlier search terms. They also considered, as a secondary focus to their study, literature on 
antidepressant-related suicide, using MEDLINE and the terms ‘suicide/all subheadings’, 
again in combination with the earlier search terms. 
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5. RESULTS  
 
5.1 QUANTITY AND QUALITY OF RESEARCH AVAILABLE  
 
Overall, eight individual meta-analyses were identified,
7,13,16,22,23,24,25,26
 two guidance papers
6,7
 
and one systematic review,
27
 all of which considered the relative clinical efficacy and 
effectiveness of SSRIs compared to TCAs.  
 
Altogether, six key reviews of published cost-effectiveness/economic evaluation based 
studies were found.
28,29,30,31,32,33
 In total, the search strategy identified 20 published studies 
which provided a formal evaluation of cost-effectiveness for at least one SSRI, against at 
least one reference TCA. Studies which were restricted to comparisons across different 
SSRI drugs were not included as these fell outside the report brief. 
 
5.2 EVIDENCE OF EFFECTIVENESS  
 
The relative clinical efficacy and clinical effectiveness of SSRI and TCA antidepressants 
have been explored through an extensive body of randomised controlled studies conducted 
world-wide. These studies have been undertaken in a range of different health care settings, 
but were most commonly conducted within a secondary care in-patient or out-patient 
context. This bias towards secondary care causes problems in generalising results and 
conclusions to a primary care setting, where the profile of patients may be very different, 
often with less severe illness, and where optimal treatment is more difficult to attain. 
 
Another general criticism of the existing RCT evidence base is that actual patient definitions 
and/or inclusion criteria tend to vary greatly between trials. Also, actual patient numbers 
remain relatively small, meaning that results of statistical significance are very difficult to 
obtain from individual trials alone.  
 
The existence of this large set of poorly powered randomised studies has lead to a number 
of published attempts to summarise and pool such data using formal techniques of meta-
analysis. The following provides a brief overview of the scope of the meta-analyses 
evidence base, in particular with reference to clinical efficacy and effectiveness, and 
highlights the key messages and interpretations of outcomes drawn from these studies. 
Table 4 provides a summary of the meta-analyses. 
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Table 4 Published Meta-Analyses - Summary of Designs 
Authors  RCTs Drop-out Efficacy Setting Antidepressant Reference Drugs Included 
     SSRIs Comparator Drug (definitions as per Hotopf et al., 1997) 
Song et al., 1993
16
 63 Overall Y Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine 
Old TCAs;      amitriptyline, imipramine 
New TCAs;    dothiepin, nortriptyline, desipramine, clomipramine, 
doxepin 
Heterocyclic;  bupropion, maprotiline, mianserin, nomifensine, trazodone 
Montgomery et 
al.,1994
22
 
42 Side-effect 
/ Failure  
N Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine 
Old TCAs        amitriptyline, imipramine 
New TCAs;     clomipramine, dothiepin, doxepin 
Montgomery et al. 
1995
26
 
67 Side-effect 
/ Failure 
N Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine 
Old TCAs;       amitriptyline, imipramine 
New TCAs;     clomipramine, dothiepin, doxepin, desipramine 
Anderson et al. 1995
23
 62 Overall / 
Side-effect 
/ Failure 
N Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine / 
citalopram 
Old TCAs;       amitriptyline, imipramine  
New TCAs;      dothiepin, desipramine, clomipramine, doxepin 
Hotopf et al., 1997
13
 105  Overall N Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine 
Old TCAs;       amitriptyline, imipramine 
New TCAs;     dothiepin, nortriptyline, desipramine, clomipramine, 
doxepin 
Heterocyclic;   bupropion, mianserin, trazodone, maprotiline, amineptine, 
nomifensine 
 
CCOHTA 1997
34
 104 Overall/ 
Side-effect 
/ Failure 
Y Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine 
Old TCAs;      amitriptyline, imipramine 
New TCAs;     dothiepin, doxepin, clomipramine, , maprotiline, 
oxaprotiline, desipramine, nortriptyline  
Heterocyclic;   mianserin, trazodone, moclobmide, bupropion, 
amineptime, nomifensine, lofepramine 
 
North of England 
Guidelines 1999
7
 
98 Overall Y Secondary/ 
Primary care 
fluoxetine / sertraline / 
paroxetine / fluvoxamine / 
citalopram  
+ 
nefazodone / venafaxine 
(related drugs) 
Old TCAs;      amitriptyline, imipramine 
New TCAs; dothiepin, doxepin clomipramine,  maprotiline, 
desipramine, nortriptyline  
Heterocyclic; mianserin, trazadone, moclobemide, bupropion, 
amineptine,  lofepramine, 
Anderson et al., 1998
25
 
 
 
25 Overall / 
Side-effect 
/ Failure 
Y In-patient  fluoxetine / paroxetine / 
fluvoxamine / citalopram 
Old TCAs;      amitriptyline, imipramine 
New TCAs;    clomipramine, maprotiline, desipramine 
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Table 5 Published Meta-Analyses - Summary of Outcomes 
 Outcomes Measured (SSRIs vs TCAs) 
 
Treatment Effect  
(Hamilton Rating Scale) 
Withdrawals 
due to Side-
effects 
(Odds Ratio) 
Withdrawals 
due to Lack of 
Efficacy 
(Odds Ratio) 
Overall 
Withdrawal 
Rates  
(Odds Ratio) 
Overall Withdrawal Rates due to Drug Type  
(Odds Ratio) 
Reference 
SSRIs vs. 
Classical 
TCAs 
SSRIs vs.   
Non-SSRI 
  * = relative risk Old TCA Newer TCA Heterocyclics 
Song et al., 1993
16
 
0.004
†
 
(-0.096 to 0.105) 
0.805 
(0.648 to 1.001) 
1.022 
(0.801 to 1.034) 
0.95 
(0.816 to 1.107) 
   
Montgomery et al., 1994
22
 
 
 0.68 
(0.57 to 0.80) 
1.18 
(0.89 to 1.57) 
    
Montgomery et al., 1995
26
 
 
 0.70 
(0.61 to 0.79) 
1.09 
(0.91 to 1.32) 
    
Anderson et al., 1995
23
 
 
 0.68 
(0.58 to 0.79) 
1.13 
(0.90 to 1.42) 
0.87 
(0.75 to 1.00) 
   
Hotopf et al., 1997
13
 
    
0.86 
(0.78 to 0.94) 
0.82 
(0.72 to 0.92) 
0.89 
(0.74 to 1.06) 
1.02 
(0.78 to 1.35) 
CCOHTA 1997
34
 
-0.06 
(-0.20 to 0.09) 
-0.01 
(-0.08 to 0.06) 
      
North of England 1999
7
   
  0.87* 
(0.80 to 0.95) 
   
Anderson et al., 1998
25
   
0.66* 
(0.50 to 0.87) 
1.13* 
(0.84 to 1.51) 
0.88* 
(0.75 to 1.03) 
   
†
Pooled difference of mean Hamilton scores over 20 randomised trials which provided full standard deviation clinical efficacy data. 
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Table 6 Summary of Meta-Analyses 
 Outcomes Measured 
 
Withdrawals due 
to Side Effects 
(% patients) 
Withdrawals due 
to Lack of 
Efficacy 
(% patients)  
Overall 
Withdrawal 
Rates  
(% patients)  
Reference 
SSRIs vs.  TCAs SSRIs vs.  TCAs SSRIs vs.  TCAs 
Song et al., 1993
16
 15.4% vs 18.8% 7.0% vs 6.8% 32.3% vs 33.2% 
Montgomery et al., 1994
22
 14.9% vs 19.0% 6.0% vs 5.1 % - 
Montgomery et al., 1995
26
 13.9% vs 18.8% 7.4% vs 6.8% - 
Anderson et al., 1995
23
 14.4% vs 18.8% 7.3% vs 6.8% 30.8% vs 33.4% 
Hotopf et al., 1997
13
 - - 28% vs 31% * 
CCOHTA 1997
34
    
North of England 1999
7
 - - 27.7% vs 32.7% 
Anderson et al., 1998
25
 **  9.1% vs 14.2% 11.6% vs 10.0% 25.5% vs 29.0% 
 
*calculated as per Anderson et al. 1995 methodology 
** in-patients only study  
 
 
Tables 5 and 6 summarise the results from the identified meta-analyses. Outcomes are 
reported as the standardised difference for the Hamilton Depression Rating Scale (HDRS) 
for depression and as an odds ratio (OR) of the drop-out rate of patients in the SSRI group 
relative to that in the comparator drug group. Additionally, 95% confidence intervals are 
provided for both measures. 
 
Clinical Efficacy 
 
Only four of the meta-analyses considered explicitly clinical efficacy as a specific outcome 
measure, using standardised methods to combine studies with different outcome rating 
scales.
7,16,25,34
 The majority of the randomised trials have used the HDRS as a tool for 
measuring the severity of a patient’s episodic illness. 
 
Song et al. considered treatment effect, using elements of the HDRS, from 63 randomised 
double-blinded studies which had compared an SSRI to a non-SSRI antidepressant.
16
 
Median trial duration was six weeks, with the longest trial period observed at twelve weeks 
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of active treatment. The overall conclusion was that there were no significant differences 
between the two drug groups in terms of their clinical efficacy. 
 
The resulting Effective Health Care Bulletin (EHCB) was strongly informed by the findings of 
the Song et al. study, and was distributed to all GPs in England and Wales.
2
 This document 
was intended to provide information on the prevalence and recognition of major depression 
and the effectiveness of potential treatment options available to primary care teams. The 
document attempted to use the evidence existing at the time to influence the future 
prescribing of antidepressants, recognising the potential cost implications of wide-spread 
SSRI usage. The efficacy conclusions mirrored those expressed by Song et al., in that 
SSRIs were generally considered to have equal clinical effect to TCAs, although the 
evidence base was recognised as being dominated by studies of small patient numbers with 
no distinct sub-group analysis to suggest target patient groups. 
 
The North of England Evidence-based Guideline Development Project shared common 
authorship with the Song et al. study (and subsequent EHCB) and was centred on a revised 
meta-analysis of key RCTs considering relative efficacy, overall drop-out rates, effective 
doses, toxicity and safety between SSRIs (including lofepramine) and TCAs. The study 
considered data from 98 RCTs, published before February 1997. It found a slight clinical 
efficacy advantage in favour of TCAs, but deemed it to be of 'uncertain practical 
importance'. On average, the results suggested that in 51.4% of cases a TCA-treated 
patient would have a lower HDRS score than one on SSRIs and SSRI-related drugs. The 
authors effectively concluded that efficacy was the same between the two antidepressant 
drug classes. 
 
The Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA) group  
was able to review 104 individual RCTs comparing SSRIs with TCAs, and concluded that 
there was no statistically significant differences in terms of clinical efficacy (measured as an 
overall efficacy effect) between any groups of antidepressants.
34
 This meta-analysis 
included trials against placebo which did confirm conclusively the efficacy of SSRIs over a 
‘no-treatment’ option. 
 
Finally, Anderson et al. published a revised meta-analysis building upon a previous study 
but, importantly, restricted the analysis to in-patient studies only.
25
 They included trials of the 
heterocyclic drug, maprotiline, previously excluded from their original study. Clinical efficacy 
data from 25 RCTs were considered. The analysis considered a general split of the TCA 
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group into dual-action (i.e. those inhibiting both 5HT and noradrenalin re-uptake) and single-
action (noradrenalin re-uptake only). The study concluded that only dual-action TCAs were 
more efficacious than SSRIs. Overall, there was a statistically significant efficacy difference, 
in favour of TCAs, when all TCAs were grouped together. The authors commented on the 
low numbers in the trials (median <40 patients) and the likelihood that the patient group had 
more severe depression than commonly seen in general practice. 
 
Treatment Tolerability 
 
The majority of the meta-analysis studies focused on the relative patient acceptability of 
SSRIs, assessed through analyses of discontinuation, or drop-out rates, as a proxy for 
patient adherence / treatment tolerability.  
 
Song et al. compared overall drop-out rates for SSRIs and TCAs finding no significant 
differences. They concluded that SSRIs, as a first-line therapy, would be expected to be 
less cost-effective than non-SSRI antidepressants.
16
 Importantly, the study included data 
from 12 trials which used newer TCA-related drugs (or heterocyclics), including trazodone, 
maprotiline, mianserin, bupropion and nomifesine. This inclusion has been criticised by 
some for introducing potential bias against SSRIs, as newer TCA-related drugs tend to have 
a better adverse-event/tolerability profile than seen with older TCAs.  
 
Montgomery et al. published two meta-analyses, in 1994 and 1995.
22,26
 The second meta-
analysis, extending the original time-period and scope of the first, included evidence from 67 
RCTs, of which 10 had placebo arms. Analysis of drop-out rates were based on 3,474 
SSRI-treated patients and 3,378 TCA-treated patients. However, the analysis was restricted 
to trial data which used older first-generation TCAs as comparator drugs. This decision was 
justified by the argument that the newer generation drugs (heterocyclics), although having 
better side-effect profiles, were not 'true' TCAs and that their inclusion into the study would 
introduce bias against SSRIs. The analysis of Song et al. was strongly criticised by 
Montgomery et al. for the inclusion of such heterocyclic comparator drugs.  
 
The analyses reported a small, but significantly lower, discontinuation rate, due to adverse 
effects, for SSRIs than for TCAs (13.9% versus 18.7%; for SSRIs and TCAs respectively – 
from the second Montgomery study). The equivalent odds ratio was quoted as 0.7 (95% CI; 
0.61 – 0.79). However, withdrawals due to lack of efficacy were comparable between the 
two groups (7.4% versus 6.8% for SSRIs and TCAs respectively), as were those related to 
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treatment failure/lack of efficacy. This study was criticised for not having analysed overall 
‘all-cause’ drop-out rates. 
 
Anderson et al. considered differences in drop-out rates due to side-effects and lack of 
efficacy as well as in overall ‘all-cause’ drop-out rates.
23
 As with Montgomery et al., RCTs 
were restricted to those with comparator arms based on older first generation TCAs only,  
justified on the basis that such drugs were ‘not true TCAs and that they did not represent a 
true alternative treatment option’. Thus, specific trials using heterocyclic TCA-related drugs, 
originally included in the analysis of Song et al., were excluded (14 in total).  
 
The main findings were again similar to those of Montgomery et al., in that TCAs were 
clearly less well tolerated than SSRIs. The difference between TCAs and SSRIs was more 
noticeable for drop-out due to adverse effects (OR 0.68, 95% CI 0.58 to 0.79) than for 
overall drop-out (OR 0.87, 95% CI 0.75 to 1.00). However, the differences in overall drop-
out rates were relatively small in absolute terms (30.8% vs 33.4% for SSRIs and TCAs); this 
equates to three avoided drop-outs for every 100 cases treated, or a number needed to 
treat (NNT) of around thirty patients. In contrast, there was no significant difference between 
withdrawals due to treatment failure, again confirming the original findings of Montgomery et 
al. The study has been criticised by some for its exclusion of heterocyclic comparison trials, 
and, in particular, for its statement that these drugs (in particular lofepramine and 
trazodone) are ‘of minor importance clinically in terms of numbers of prescriptions’ and are 
‘nearly as expensive as SSRIs’. 
  
Hotopf et al. produced a further meta-analysis of 105 RCTs.
13
  The study set out to 
investigate whether advantages in drop-out rates in favour of SSRIs remained present when 
SSRIs were compared to three sub-groups of TCAs, namely: older TCAs; newer TCAs; or 
heterocyclics (Table 2 has been grouped by this categorisation). The analysis concentrated 
on an assessment of the overall drop-out rate in the belief that this represented a ‘more 
accurate reflection of treatment acceptance’. 
 
Overall, there was a total discontinuation rate of 31%, with a relative risk (RR) for SSRIs of 
0.9 (i.e. an absolute 3% reduction in drop-out rate). Of the three sub groups, it was only 
against the older TCAs that SSRIs showed any significant advantage in terms of overall 
drop-out rate (OR 0.82, 95% CI; 0.72–0.92). Due to the large number of such trials making 
comparisons with older TCAs, this advantage was also reflected in the overall drop-out rates 
when all studies were pooled (OR: 0.86, 95% CI; 0.78–0.94).  Hotopf rightly commented on 
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the low number of studies comparing SSRIs with heterocyclic drugs. This led to very wide 
confidence intervals and suggested a need for further randomised trial evidence in respect 
of these drugs. In conclusion, the authors argued that it was only in relation to older TCAs 
that SSRIs could be considered to have improved significantly the drop-out rate and, hence, 
effectiveness. The most important point raised was that combining the results of all TCA 
groups together masks great differences between the individual drugs themselves. 
 
The North of England Guidelines (1997) reported that overall drop-out rates were 4-5% 
lower (in absolute values) with SSRIs, than with TCAs (27.7% vs 32.7% respectively).
7
 This 
equated to a relative risk of 0.87 (95% CI: 0.80-0.95). However, they rightly point out that 
this result, as with all the other meta-analyses, is measured over relatively short time spans, 
averaging six-weeks. The authors considered overall drop-out rates separately against the 
two most commonly referenced TCAs  (i.e. amitriptyline and imipramine) - the relative risks 
for SSRIs were 0.87 (95% CI: 0.77-0.99) and 0.91 (95% CI: 0.77-0.99) respectively. An 
interesting observation was that differences in drop-out rates in favour of SSRIs increased 
over time, when results were considered in chronological order. This possibly reflects the 
wider inclusion of previously TCA-challenged patients, improvements in reporting or general 
differences in patient management. However, there is no solid evidence to draw any firmer 
conclusions from this observation. The authors also went on to analyse trials that compared 
TCAs to lofepramine (a newer TCA-related drug associated with a much lower rate of 
adverse events). There were no significant differences in either efficacy or drop-out rate 
from other antidepressants included in 17 RCTs. 
  
The CCOHTA study measured differences in overall drop-out rates and again found no 
significant differences.
34
 As with the meta-analysis of Song et al. the group included 
comparisons with both older and newer TCAs and related drugs including: amitriptyline, 
imipramine, clomipramine, mianserin, traxodone and moclobemide.  Overall, 46 trials were 
identified which compared SSRIs with classical TCAs and 117 trials which compared SSRIs 
with other TCAs and related drugs.  
 
In their consideration of drop-out data for diagnosed depressed in-patients, Anderson et al. 
found discontinuation due to adverse effect was significantly lower with SSRIs than TCAs 
(9.1% vs 14.2%); with an OR of 0.66 (95% CI: 0.5-0.87).
25
 However, this significance was 
not repeated when the overall drop-out rate was considered, although there was a trend 
towards SSRIs (25.5% vs 29%).  
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Toxicity and Suicide 
 
The published Office for National Statistics (ONS) mortality statistics for 1997 revealed 400 
antidepressant-related deaths in England and Wales (220 male/180 female).
35
 Of these 168 
(42%) were clearly suicide attempts and 67 (17%) were the result of accidental poisonings. 
The remaining 41% had no known purpose designated. Overall, clear suicide/self-harm 
related deaths totalled 3,424 for the same period, implying that roughly 5% of suicides 
(168/3,424) are antidepressant related. Hotopf et al. previously identified a UK suicide rate 
of 8 per 10,000, of which 7% were associated with an overdose of  antidepressants.
27
 
 
In a recent review of antidepressant-related suicide, Jick et al. reviewed the medical records 
of a population of approximately four million across England and Wales over the period 
January 1988 to February 1993, through the general practice VAMP database (roughly 
representing a 7% national sample).
36
 Using recorded diagnosis codes and prescribing data 
the authors analyse suicide rates, mode of suicide and person-years at risk for individual 
antidepressants. The results revealed that 143 people were identified as having died 
through suicide and 172,598 people received at least one antidepressant prescription. 
Overall, the rate of suicide was 8.5 per 10,000 years risk, with notably higher rates for males 
(relative risk 2.8). Dothiepin was used as the reference point (given its common use) and 
relative risks were calculated for individual antidepressants. Although overall suicide rates 
appeared higher for those taking newer medications, such as fluoxetine (relative risk 2.1) 
and mainserin (relative risk 1.8), rates of suicide through overdose were noticeably much 
higher for classical TCAs. One explanation for this is that, in the absence of randomisation, 
those having  greater assessed risks of suicidal tendencies are likely to be prescribed less 
toxic drugs, therefore, biasing the results. Patients on less toxic drugs had significantly 
higher rates of previous antidepressant usage. Overall the study found that 14% of the 
recorded suicides were associated with antidepressant overdose. 
 
This mirrored previous findings from a Swedish study of antidepressant-related suicide.
37
 
This study considered data for a much larger number of suicide cases (n=3400) and found 
that less than 16% had detectable levels of antidepressant present. Of these, only a third 
had levels interpreted as contributing to death through toxicity (approximately 5-6%).  
 
Taken together, such findings appear to suggest that moving all antidepressant prescribing 
towards the less toxic TCAs and SSRIs could potentially avoid somewhere between 5-10% 
of all suicides. However, caution needs to be taken in drawing such conclusions, as the link 
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between depression and suicide remains a complex issue. It is clear from the Jick et al. 
Study
36
 that suicidal patients prescribed non-toxic medication can, and do, seek alternative 
methods of suicide. However, it is also true that expanding the use of less-toxic drugs would 
potentially avoid accidental overdose in low suicide risk patients who are currently on TCA 
medication. Roughly 50% of such antidepressant-related deaths remain accidental. 
 
The North of England guidelines reviewed data on poisonings and fatalities and levels of 
antidepressant prescribing for the UK, covering the period 1993-95.
7
 These data suggested 
an overall mortality rate due to overdose on antidepressants of roughly 30 in 100,000 years 
risk. Restricting this analysis to TCAs (non-lofepramine), this rate rose to 170 in 100,000 
years risk. Comparative rates for lofepramine (1.7 in 100,000) and SSRIs (1 in 100,000), 
confirm that the risk of suicide through antidepressant toxicity is much reduced in the less 
toxic drugs. 
 
Freemantle et al. considered the relative risks of suicide through antidepressant overdose 
and concluded that, on a cost per life saved basis, the costs of moving towards the routine 
use of first-line low-toxic SSRI drugs were high (average £50,000 per life year saved) and 
that other approaches to suicide avoidance should be evaluated.
38
 However, Freemantle 
assumed the same clinical effectiveness and tolerance for the two drug groups. If, due to 
sub-therapeutic dosage and poor compliance, TCAs are less effective, then the incremental 
cost per life year values for SSRIs is likely to be lower. There has also been criticism of the 
fact that the overall suicide rate was not used, again from the viewpoint that alternative 
methods can be sought out by determined suicidal patients. 
 
As well as considering the potentially achievable benefits of life years saved, through wider 
usage of drugs with a low toxicity, and the associated costs, it is important also to consider 
the influence of this strategy on para-suicides, which can present a significant cost burden 
to the NHS.  
 
The potential cost of health care support in cases of attempted suicide from antidepressant 
overdose has been considered by a US study by Revicki et al.
39
 The study reviewed records 
on 136 patients who presented to emergency health services with overdoses of 
antidepressant (121 TCA related and 15 fluoxetine). Although 84% of TCA overdose 
patients had some degree of stay in intensive care, none of the fluoxetine patients required 
such care. TCA patients also had much longer mean lengths of stay (3.6 days versus 0.73 
days respectively). Mean medical costs were significantly lower for the fluoxetine patients 
(US $1,269 versus US$5,764). 
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D’Mello et al.
40
 also considered the same issue in a retrospective US review of 24 cases of 
antidepressant-related overdoses. This study also found significantly shorter lengths of stay 
for SSRI patients (3 days versus 7 days) and significantly lower health care costs (US 
$5,379 versus US$22,923), although the precise build-up of these costs was not stated. 
 
5.2.1 Summary of Key Efficacy and Effectiveness Issues 
 
The following summarises the main themes of the current evidence base related to SSRI 
use as a first-line treatment for major depression. 
 
Drug Efficacy - The general consensus is that there appears to be no significant difference 
between any of the antidepressant groups in terms of efficacy. Irrespective of the viewpoint 
taken, none of the meta-analyses appears to reveal any meaningful difference in overall 
effect size, whether measured using the Clinical Global Impression score or HDRS. TCAs, if 
anything, appear to be slightly more efficacious than SSRIs, but the difference is argued as 
having little clinical importance and fails to reach a statistical significance. As expected, the 
only significant differences for SSRIs were when compared to placebo.  
 
Drug Tolerability - There is clear variation in the reported drop-out rates for SSRIs and 
TCAs taken from individual trials. The conclusion from the published meta-analyses is that 
SSRIs and related drugs are generally better tolerated than the older TCAs. Treatment 
withdrawals due to side-effects are less common when using SSRIs than TCAs. The typical 
absolute difference in overall drop-out rate appears to be 4-5% in favour of SSRIs, with 
overall drop-out rate for TCA-related drugs at around 30-35% (or 14-19% if taken as drop-
out related to adverse effects). What remains uncertain is the true difference between TCAs 
and SSRIs in terms of longer-term patient adherence. 
 
Adverse Effects Profile  - SSRIs are generally associated with more frequent cases of 
nausea, anorexia, diarrhoea, anxiety, agitation, insomnia, nervousness compared to TCAs, 
which, in turn, are associated with more frequent cases of dry mouth, constipation, blurred 
vision, dizziness and weight gain.
34
 SSRIs have fewer sedative, cardiovascular, 
anticholinergic or psychomotor adverse effects and do not lead to weight gain, but do have 
more gastro-intestinal side-effects.
34
 SSRIs have a much reduced adverse effect profile 
over traditional TCA drugs, as do the newer TCAs/heterocyclics. 
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Relapse and Recurrence Rates - It has been suggested that there are benefits of improved 
recurrence/relapse rates towards SSRIs.
41
 However, there is currently little evidence of the 
relative risk of relapse between SSRIs and TCAs, and relapse is always possible for those 
patients suffering from depression. More longer-term studies are required. 
 
Safety and Toxicity - SSRIs and lofepramine appear less toxic in overdose than older TCAs, 
as can be seen from the analysis of the North of England guidelines. Earlier studies suggest 
that overall suicide rates between patients do not vary according to antidepressant 
medication, implying that suicidal tendencies are more complex than simply having the 
means to hand. Another aspect of the risk of TCA-related overdose is that the presence of 
drugs in the home presents a means of suicide to people other than the patients 
themselves. Therefore, a wider assessment of family situations may be necessary in the 
process of considering appropriate medications for patients with depression. Further 
research is needed to judge the true suicide impacts of widespread SSRI usage in terms of 
avoided healthcare costs, life years saved and, importantly, the costs of attempted suicide.  
 
General Points 
 
These efficacy and effectiveness results come largely from well designed controlled trials 
conducted within an environment designed to optimise levels of therapeutic dosage and 
levels of patient adherence. Also, and very importantly, the studies are predominantly 
secondary care based. Therefore, it is likely that the disadvantages of TCAs, especially 
used in primary care, are to some extent masked. However, despite these potential biases, 
significant differences in rates of adverse effects have been found between SSRIs and 
TCAs.  
 
An obvious general criticism of the randomised trial evidence base is that the low patient 
numbers mean that statistical significance is only observed for large differences in treatment 
effects, and that the very short time periods involved (maximum 12 weeks) are likely to 
misrepresent the situation further. Long-term rates of drop-out and other potential 
differences remain unknown. 
 
Although the published meta-analyses have all adopted what appear to be sound and 
recognised statistical methodologies in the process of the pooling of data, there are 
differences in analytical approach which have led to different interpretations of the RCT 
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evidence base. In particular, there are two key areas upon which mental health researchers 
have differing views. 
1) Choice of Comparator Drugs 
 
Firstly, there is clear disagreement as to what justifies a sound and clinically relevant choice 
of comparator antidepressant drugs. Whilst some argue that the inclusion of newer 
heterocyclic drugs is not appropriate, and that comparisons should be made with the most 
commonly prescribed drugs (e.g. amitryptiline, imipramine, dothipen and clomipramine) 
rather than the ‘best’ alternative treatment,
22,23
 others clearly dispute this point of view.
7,16,27
 
The counter-argument for including heterocyclic drugs is that they are now prescribed at 
significant volumes within the NHS. It is also stressed that the tolerance advantages of 
SSRIs may well hold true for newer TCAs, such as lofepramine, at much lower costs. 
 
An analysis of Prescription Pricing Authority data for antidepressants tends to support this 
point of view, in that both trazodone and lofepramine are prescribed in significant volumes, 
indicating that heterocyclics are being widely used in clinical practice (see Table 2). It is also 
clear that the cost of these drugs is significantly lower than the branded versions of the 
SSRIs (although this may alter when patents for SSRIs begin to elapse).  
 
The combined findings of all the meta-analyses suggest that it is inappropriate to consider 
all TCA and TCA-related drugs as having equivalent clinical effectiveness. Of all the 
published meta-analyses, Hotopf et al. 1997
13
 and the CCOHTA report
34
 provide what 
appears to be the clearest considerations of both comparative efficacy and drop-outs 
related to different sub-groups of antidepressants (including comparisons of SSRIs with 
older TCAs, newer TCAs and heterocyclics). Such sub-group analysis of drop-out rates 
supports the existence of at least three sub-classes of these TCA antidepressant drugs, 
when both tolerability profiles and treatment costs are taken into account (see Appendix). 
 
2) Choice of Drop-out Measure 
 
There is also wide debate over which precise measure of drop-out rate provides the most 
reliable and informative measure of tolerability or effectiveness. It is argued strongly that 
reasons for discontinuation are far more complex than a response to adverse effects alone, 
and that overall drop-out rates are far more important in considering treatment 
effectiveness. As such, the majority of meta-analysis studies have used on overall all-cause 
drop-out rate as a proxy for tolerability of treatment.
13
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Further debate on drop-out rate is related to the interpretation of study outcomes in the form 
of either relative, or absolute, difference. Some researchers stress the low absolute 
differences in overall drop-out rate, as suggested by the meta-analysis at around 4-5%.
42,43
 
This is argued to have little consequence when considering the cost-effectiveness of 
treatment as studies have shown that patients failing on TCAs can switch successfully to 
SSRIs with very similar long-term continuation rates, as with patients on first-line SSRI 
treatment.
44
 However, an equally vocal group of researchers takes the opposite view on this 
issue, believing that even a small difference can be a clinical advantage to patients.
45
 
 
5.3 ECONOMIC ANALYSIS 
 
5.3.1 Background 
 
With NHS costs of SSRIs currently standing at around 5-6 times those of typical TCAs, 
there is an obvious interest in not only the relative clinical effectiveness of SSRIs and TCAs, 
but also their overall economic effectiveness (typically judged in terms of a cost per patient 
treated, cost per recovery or cost per Quality Adjusted Life Year). The real issue is whether 
the current higher drug costs for SSRIs are worth paying given the potential benefits. These 
benefits are said to be a reduction in adverse effects/toxicity, improved compliance, and 
reduced risks of suicidal overdose. In direct response to these concerns there has been a 
number of studies, published over the last decade, aimed at evaluating the relative cost-
effectiveness of different classes of antidepressant drugs. 
 
The essential research questions remain: 
 
1. Can the higher costs of SSRIs be offset by the potential reduction in other treatment-
related costs?  
 
2. Can SSRIs provide marginal patient benefits value in terms of improved quality of life or 
acceptable levels of cost per additional recovery? 
 
The evaluation of the pharmacoeconomics of drug treatments for depression is fraught with 
difficulties and, at present, can at best provide only an indication as to the relative cost-
effectiveness of interventions. Many of the key issues in addressing such research 
questions have been discussed previously and highlighted in the published literature. A 
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recent series of papers by Henry et al. discusses many of the problems faced in using 
formal RCT studies to evaluate both the clinical and cost-effectiveness of 
antidepressants:
46,47
   
 
 Chronic recurrent nature of disease  Graduation of severity 
 Lack of adequate clinical reality of RCTs  Optimal dosing of TCAs 
 Tendency for compliance to be optimal in RCT  Limited to study setting 
 Exclusion of more complicated patients  
 Inadequate consideration of long-term cost impacts 
 Inadequate costing of adverse events 
 
Many of these criticisms of using RCTs to evaluate economic effectiveness are general 
points and concerns, rather than being specific to the area of depression. 
 
The purpose of the remainder of this section is to provide an overview of the quantity and 
quality of the existing health economic evidence for SSRIs and to reflect on the likely study 
design which would provide the standard of evidence that would illuminate the outstanding 
issues.  
 
5.3.2 Methodology & Approach 
 
One of the most thorough reviews of the current state of evidence-base regarding the cost-
effectiveness of antidepressants comes from a publication by Woods & Baker, 1999.
31
  
 
More recently, there have been five additional published reviews of the cost-effectiveness of 
SSRIs versus TCAs. Wilde et al. focused exclusively on the relative effectiveness of 
fluoxetine (Prozac™) against standard TCAs.
30
 Further studies consider the case for SSRIs 
vs. TCAs within the context of a wider overview of pharmacoeconomics of antidepressant 
therapy.
28,29,32,33
  
 
Given the considerable volume of previous work, and the apparently thorough 
methodologies adopted in their search strategies, the chapter has been based on a 
combined summary of the findings of all of these peer-reviewed studies.  
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5.3.3 Forms of Economic Assessments Identified 
 
Full cost-benefit analyses, where both the costs of treatment and treatment benefits are 
expressed in purely monetary terms, using techniques such as willingness to pay, are 
notoriously difficult to formulate. This is reflected in the types of economic evaluations 
identified, which were predominantly cost-effectiveness studies.  
 
More influential than the exact type of economic assessment is the analytical methodology 
adopted in evaluating the evidence of health benefits and costs. Overall, the approaches 
adopted by the identified studies included in this review can be categorised into three types.  
 
 Prospective randomised studies; 
 Retrospective reviews of case-data / administrative data-bases; 
 Clinical decision modelling / simulation analysis. 
 
The vast majority of studies (13 out of 20) identified used a modelling approach, with a 
number of other studies (6 out of 20) retrospectively reviewing the outcomes and treatment 
costs of patients using historical database records (see Tables 7 and 8).  Importantly, only 
one randomised study was identified which provided evidence on the cost-effectiveness of 
SSRIs versus TCAs.  
 
5.3.4 Key Prospective Trial Design Studies 
 
Simon et al. published the first, and to-date only, randomised study of antidepressants, 
comparing the first-line use of SSRIs (fluoxetine) against two control arms both based on 
TCAs (imipramine and desipramine).
44
 This study was based within a US cohort including 
major depression patients (n=536) who were treated within the context of a primary care 
system. The costing element of the study was based on a health care provider prospective 
and as such targeted direct costs only, ignoring potential indirect costs such as family care, 
employment costs and patient costs.  
 
The six-month duration study attempted to provide a more real-world clinical setting than 
may have been possible with the strict constraints of a formal RCT. As such, the study was 
blinded only to clinical assessors and not patients or primary clinicians. Patient recruitment 
was also designed to ensure a more representative sample, although suicidal tendencies 
and recent use of antidepressants were employed as exclusion criteria. Switching between 
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Table 7 Retrospective Cost-effectiveness Studies 
Reference / Setting / 
Size / Dates 
SSRI 
Therapy 
TCA 
Reference 
Study Design and Data Sources Principal Outcomes Results 
Sclar et al. (1994)
48
 
US 
N=701 
1/1/89-10/31/93 
Fluoxetine  
 
Amitriptyline 
Nortriptyline 
Desipramine 
HMO patients staying on initial 
antidepressant for 12 month period. 
Treatment switching excluded. 
Depression related 12 month  healthcare 
expenditure 
Fluoxetine < TCA 
Skaer et al. (1995)
49
 
US 
N=823 
1/1/89-6/30/94 
Sertraline  
 
Amitriptyline 
Nortriptyline 
Desipramine 
HMO single episode depressed patients 
staying on initial antidepressant for 12 
month period Treatment switching 
excluded. 
As for Sclar et al., 1994 Sertraline < TCA 
Forder et al. (1996)
50
 
UK 
N=398 
dates not stated 
Sertraline 
 
All TCAs General practice patients selected from 
clinical trial & matched control individuals 
Intention-to-treat analysis. 
Direct and partial indirect 12 month cost per 
successfully treated patient and per patient. 
(Included accommodation and living costs). 
Sertraline < TCA 
 
 
Smith & Sherrill. (1996)
51
 
US 
N=152 
1994 
SSRIs  
 
TCAs HMO, ICD-9 major depression, received 
antidepressant > 3 month, excluded if 
switched drug. 
Depression related 12 month healthcare 
expenditure. 
SSRIs = TCAs 
Simon et al. (1998)
42
 
US 
N=5,169 
1/1/92-30/6/94 
Fluoxetine Desipramine 
Imipramine 
HMO based. Depressed patients initially 
prescribed antidepressant with a minimum 
of 6 months follow-up data available 
Intention-to-treat analysis. 
Depression related 6 month healthcare 
expenditures. 
SSRI =TCA 
Sclar et al. (1998)
14
 
US 
 
1/7/88-31/12/91 
Fluoxetine Amitriptyline 
Nortriptyline 
HMO, ICD-9 major depression . 
 
Depression related healthcare expenditures. Fluoxetine <= TCA 
 
< indicates a lower cost-effectiveness ratio (CER), and hence better cost-effectiveness. 
= indicates equivalent cost-effectiveness. 
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Table 8  Simulation-based Cost-effectiveness Studies  
Author / Year Setting SSRI 
Therapy 
TCA 
Reference 
Method Form Time 
Horizon 
Source Data Outcome Results Conclusion 
Jonsson/ 
Bebbington 
UK 1994
21
 
Primary care Paroxetine 
 
Imipramine Decision 
Tree 
CEA 12 mths Clinical trial data (6wk) 
717 pts 
Expert panel/ focus 
group 
Meta analysis 
Cost database 
Direct costs (UK) 
Cost per 
successful 
treatment 
 
Cost per treated 
patient 
No difference in cost 
 
Lower cost per successful 
patient for Paroxetine 
(£824 vs £1,024) 
SSRI < TCA 
Stewart 
UK 1994
52
 
Primary care Paroxetine 
Sertraline 
Amitriptyline 
Imipramine 
Decision 
Tree 
CEA 12 mths 
 
RCTs 
Direct costs (UK) 
Cost per 
successful 
treatment 
£491.25 Imipramine(I) 
£539.00 Amitriptyline(a) 
£581.46 Sertraline(s) 
£547.65 Paroxetine(p) 
i < a < p < s 
McFarland 
1994
53
 
Primary care Paroxetine 
 
Imipramine Decision 
Tree 
CEA 12 mths Primary care data 
base 
Cost per patient No differences SSRI <= TCA 
Hatziandrou et al., 
1994
54
 
Young 
female 
Sertraline 
 
Dothiepin Markov 
State 
Model 
CUA 24 mths Life-time costs  
2 cohorts of 35 year 
old women 
Expert panel 
 
Cost per QALY Cost : £3407 vs £1648 
QALY : 14.9  vs 14.1 
Marginal cost/QALY = £2172 
Sertraline more 
costly, but looks cost 
effective 
Lapierre et al. 
1995
55
 
Primary care Paroxetine 
 
Imipramine Decision 
Tree 
CEA 12 mths Clinical trial data (6wk) 
717 pts 
Expert panel/ focus 
group 
 
Direct cost per 
patient 
Lower for Paroxetine 
$Can1679 Paroxetine 
$Can1793 Imipramine 
SSRI < TCA 
Einarson et al.,  
1995 
56
 
A: In-patient 
B: Out-
patient 
Ventafaxine 
(v) 
SSRIs (s)  
TCAs (t) 
HCAs (h) 
  
Clinical 
Decision 
Analysis 
CEA 6 mths Meta analysis 
Expert panel 
Direct costs (Can) 
Direct cost per 
symptom-free 
day 
HCAs most cost effective in 
out-patients 
Ventafaxine most cost-
effective  in out-patients 
A: v < h < t < s 
B: h < v < s < t 
Bentkover,  
1995
57
 
Primary care 
/ secondary 
care 
Paroxetine 
 
Imipramine Decision 
Tree 
CEA 12 mths Clinical trial data (6wk) 
717 pts 
Expert panel/ focus 
group 
Cost database 
Direct cost per 
patient 
Lower for Paroxetine  
$US2348 Paroxetine 
$US2448 Imipramine 
SSRI < TCA 
Hylan et al. 
1996
58
 
Primary care Fluoxetine 
 
Imipramine Decision 
Tree 
CEA 6 mths  Direct + indirect 
cost per 
successful 
treatment 
 F < I 
Nuijten et al.,  
1995 
59
 
Unspecified Citalopram 
 
Doxepin 
Amitriptyline 
Trimipramine 
Markov 
state 
CEA 12 mths Literature review 
US guidelines 
Expert opinion 
Direct costs & working 
dats (Germany) 
Direct cost per 
patient. 
Time free of 
depression 
Lower direct cost for 
Citalopram  
(DM 3764 vs DM 4577) 
More time in illness free state  
(8.2 mths vs 7.8 mths) 
C < TCA 
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Author / Year Setting SSRI 
Therapy 
TCA 
Reference 
Method Form Time 
Horizon 
Source Data Outcome Results Conclusion 
Revicki et al.  
1995
60
 
Young 
female 
 
Nefrazodone 
Fluoxetine 
 
Imipramine Clinical 
Decision 
Analysis 
CUA Life-
time 
with 9 
mths  
Life-time costs  
3 cohorts of 30 year 
old women 
expert panel 
Costs per 
patient 
Cost per QALY 
Lower cost per patient: 
$Can 50664 Nefrazodone 
$Can 52111 Imipramine 
$Can 50678 Fluoxetine 
Higher QALY figures: 
13.90 QALY Nefrazodone 
13.18 QALY Imipramine 
13.79 QALY Fluoxetine 
$Can 2009 Cost per QALY for 
Nefrazodone over TCA 
$Can 2349 Cost per QALY for 
Fluoxetine over TCA 
N < f < i 
Montgomery et al.  
1996
61
 
Primary care Nefazodone 
 
Imipramine Clinical 
Decision 
Analysis  
 
CEA 12 mths Used a single RCT 
Direct Costs (UK) 
Cost per 
successful 
treatment  
Lower cost for nefazodone 
£242 nefazodone 
£323 imipramine 
N < I 
 
 
Einarson et al.  
1997
62
 
Out-patient Ventafaxine 
(SSRIs) 
Paroxetine 
Sertraline 
Fluoxetine 
Sertraline 
Amitriptyline 
Imipramine  
Nortriptyline 
Desipramine  
Decision 
Tree 
CEA 6 mths Meta analysis 
Expert panel 
Direct costs (Can) 
Cost per patient  
Cost per 
success 
Ventafaxine and  SSRIs have 
higher costs per patient and 
success than TCAs 
Cost per patient : 
£4770 / £5072 / £6199 
respectively 
Cost per success : 
£6044 / £6633 / £9035 
respectively 
V<SSRI<TCA 
Revicki et al.  
1997
63
  
Young 
female  
Nefrazodone 
Fluoxetine 
 
Imipramine  
 
Imipramine 
step  
(i.e. followed 
by 
nefrazodone 
on failure) 
Markov 
State 
Model 
CUA Life-
time  
Life-time costs  
4 cohorts of 30 year 
old women 
expert panel 
Costs per 
patient 
Cost per QALY 
Nefrazodone has highest life-
time cost  but more QALYs 
$US 16,669 Nefrazodone 
$US 15,348 Imipramine 
$US 16,061 Imipramine step 
$US 16,998 Fluoxetine 
14.58 QALY Nefrazodone 
14.32 QALY Imipramine 
14.40 QALY Imipramine step 
14.58 QALY Fluoxetine 
 
$US 2555 Cost per QALY for 
nefrazodone over Imipramine 
step 
 
I<is<n<f 
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treatments was also freely allowed, with patients shown to be unsuited to TCAs (through a 
trial-of-treatment) being moved on to the SSRI (fluoxetine) arm. The overall design was 
intended to allow existing clinical practice to be reflected in order to assess effectiveness 
rather than efficacy. 
 
Although the mean cost of treatment was much higher (up to twice) in the SSRI (fluoxetine) 
arm, the overall treatment costs for the six-months of the study were not significantly 
different. The only significant cost differences between the treatment groups were the actual 
drug costs themselves (see Figure 3). The costs for all treatment groups were dominated by 
out-patient costs, which included not only drug costs, but also primary care visits, mental 
health team visits and other pharmacy costs. Figure 3 shows the treatment costs for each of 
the three treatment arms, with the cost of antidepressants shown separately. The drug costs 
included costs after switching. The 95% confidence intervals have also been included, as 
published.  
 
Figure 3 Treatment Costs 
Direct Costs by Initial Drug Treatment Group
£-
£500
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£2,500
Fluoxetine (Prozac) Imipramine Desipramine
Antidepressant Cost Non-Drug Costs
 
 
Discontinuation rates for the SSRI (fluoxetine) arm were found to be 10-20% less than the 
TCA arms (see Figure 4). However the data also show that patients who discontinued TCAs 
and switched to SSRIs had very similar continuation rates, suggesting that problems with 
patient adherence were short-lived, with no longer-term impact on subsequent switches in 
therapy. Interestingly, 51% of all treatment switches occurred within one month of initial 
treatment, indicating a relatively quick evaluation of treatment effectiveness. However, this 
may be due to the very close follow-up of patients. Overall, the SSRI arm experienced fewer 
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adverse reactions, in particular dizziness, constipation and dry mouth. The study found no 
significant difference between any of the three treatment groups in terms of quality of life or 
symptom-scores at the study end-point. 
 
Overall, the authors concluded that from a cost-effectiveness point of view there was no 
clear evidence of improved effectiveness for the first-line use of SSRIs in a naturalistic 
setting and that, in the light of this, the option should be left open to individual clinicians.  
The main caveat of the study must be the relatively short time period (6-months) which 
would have excluded the possibility of differences in long-term costs. Also, there is likely to 
remain a tendency for patients on TCAs to have improved adherence, optimal dosage and 
to have early switches in the treatment offered. 
 
Figure 4 Trial Outcomes 
Key Outcomes of a Naturalistic Prospective Trial of
Fluoxetine versus Two Typical TCA Drugs
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5.3.5 Key Retrospective Studies 
 
The review identified six key retrospective studies which have assessed the cost-
effectiveness of SSRIs as a first-line treatment in comparison with a TCA reference 
treatment.
14,42,48-51
 The analysis of retrospective case-series data can provide a useful 
method of ensuring a more clinically realistic view of the effectiveness and cost-
effectiveness of the treatment options. The advantages of such studies are that they are 
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quick, relatively inexpensive to perform and allow the realities of clinical practice to be 
included implicitly in their outcomes.  
 
A series of retrospective studies, by Sclar et al. and Skaer et al.
14,48,49
 have reviewed the 
records of depressed patients using computer archives. These studies included patients 
who had received treatment for 6-12 month periods on either TCA or SSRI antidepressants. 
They excluded patients who switched treatment and, hence, were likely to have biased the 
cost data in favour of TCAs. The first of these studies compared TCAs with the SSRI 
fluoxetine. A second study from the same group effectively repeated this analysis using the 
SSRI setraline. Irrespective of the SSRI group used, these studies have consistently 
showed that, despite higher drug acquisition costs, SSRIs had overall health costs no 
greater than those of TCAs, when considered over a reasonable length of time approaching 
12 months. Overall, these studies have received criticism levelled at the relatively young 
patient group, the lack of an intention to treat analysis (excluded TCA switching patients) 
and the lack of control for baseline depression severity.
64
 
 
Forder et al. provided the only UK perspective, retrospectively comparing patient costs and 
outcomes after initial treatment based on sertraline against a similar patient group under 
TCA alternatives.
50
 The most common TCA was dothiepin (110 of 196 patients). However, 
the group contained a profile of all TCA alternatives including lofepramine (19 of 196 
patients). Following up patient records over a 12 month period after the commencement of 
initial treatment, there was no observed switching to SSRIs in the TCA group (although 
switching was observed within the TCA group in 8% of cases). However, 30 patients (16%) 
did switch from SSRI to TCAs. One of the key concerns with this study would be the much 
shorter average treatment time for sertraline (168 days) compared with TCAs (278 days), 
thus reducing SSRI treatment costs disproportionately. This difference may reflect a faster 
response of patients to the drug and be a justified completion of therapy. However, the 
paper suggests that SSRI patients were more likely to remain depressed following a 
cessation of treatment, suggesting that initial treatment should have lasted longer. The 
study found around 25% of TCA patients were receiving sub-therapeutic dosages that could 
not be explained by a justified titration phase at the end of treatment, or on switching 
therapy. This confirmed the findings of the prescription analysis by Donoghue and Tylee 
regarding TCA dosages in primary care settings.
18
 Overall, the study suggested that 12-
month treatment costs for patients treated initially with sertraline are significantly lower than 
those of TCA treated patients. However, the inclusion of accommodation and personal 
consumption costs clearly inflate this difference. When restricted to 12-month direct health 
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costs only, the costs per ‘very much improved’ patient were £1,882 for SSRIs and £2,490 for 
TCAs respectively. 
 
The most recent of the studies identified was that of Simon et al.
41
 This study compared 
initial treatment with fluoxetine with TCAs (desipramine and imipramine). Again the patient 
group had a relatively low median age (40-50 years). Patients on the SSRI were observed to 
be older and to have more severe chronic illness scores and higher pre-treatment costs. 
The analysis of costs was conducted on an intention to treat basis (including treatment 
switching) and found that, in the six month period following the initial prescription, health 
service costs were higher for fluoxetine (US$2,401) than either of the two TCAs (US$2,003 
and US$1,929 respectively). Excluding the actual drug costs of antidepressants, the cost 
figures were (US$2,179, US$1,907 and US$1,861 respectively). However, when these ‘non-
antidepressant’ costs were subjected to an adjustment for age/sex/illness severity this 
relationship changed with fluoxetine having a numerically lower, but effectively equivalent, 
cost for the six-month period (US$1,963, US$2,069 and US$2,015 respectively). Over the 
period average antidepressant drug costs were US$222 for fluoxetine patients compared 
with US$60-100 for TCA treated patients. 
 
5.3.6 Key Modelling Studies 
 
The most commonly adopted methodology was the use of decision analysis and simulation  
modelling techniques to consider alternative treatment options (SSRIs versus TCAs) over 
medium to long-term periods of time (six months plus). 
 
As with all such health economic modelling approaches there are, by definition, assumptions 
taken in respect of the underlying logical structure, treatment pathways adopted, and the 
parameters used to populate the model. In most studies the majority of the model data 
(related to treatment success, drop-out rates and resource utilisation) have been taken from 
the key published meta-analyses (as previously detailed in chapter 2), specific RCTs and 
the views of clinical expert panels.  
 
To date, one of the most quoted modelling studies is that of Jonsson and Bebbington (the 
JB Study) which compared paroxetine (SSRI) with imipramine (TCA).
21
 Overall, the study 
found a cost-effectiveness advantage in favour of the SSRI as a first–line treatment, when 
considering the cost per successfully treated patient. However, this study has received 
criticism in terms of both the length of treatment adopted (12 weeks) and the assumed lack 
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of efficacy of subsequent second-line treatment switches. The relatively high drop-out rates 
in all groups, taken directly from a single RCT, were also criticised as being far greater than 
those suggested by other studies, although sensitivity analysis still maintained a cost-
effective argument in favour of SSRIs even at levels of drop-out rate of around 4%.
64
 
 
In a similar modelling exercise, Bentkover et al. used a simulation decision tree model to 
compare the treatment costs of patients with major depression using paroxetine or 
imipramine.
57
 The study derived much of its data on treatment efficacy and drop-out rates 
from the same single RCT of 717 patients, over a six week active treatment phase.
64
 The 
treatments for the patients who remained in the Dunbar trial were shown to have equivalent 
efficacy results. Dunbar et al.
64
 reported an overall drop-out rate at 42.5% for SSRIs versus 
53.5% for TCAs and drop-out rates due to adverse effects of 23% and 36% respectively. 
Importantly, these rates are far in excess of those suggested by any of the published meta-
analysis. The study used identical 10% rates of relapse during maintenance treatment, 
despite claiming some evidence of differences in favour of SSRIs. Rates of relapse following 
treatment completion were taken at 25%. Baseline results suggest virtually identical overall 
treatment costs per patient at US$2,348 (SSRIs) and US$2,448 (TCAs). The key 
differences in resource usage were those noted in costs of hospitalisations. No statement 
on cost-effectiveness was made explicitly. This trial had very similar outcomes and design to 
an earlier trial by Lapierre et al.
55
 (having Bentkover as a co-author). 
 
A later revision of the JB Study by Woods et al. used the same basic model structure but, 
after revising assumptions on drop-out rates and treatment efficacy, found that TCAs 
became more favourable in terms of their cost-effectiveness ratios.
65
 This study assumed 
that initial treatment lasted for 20 weeks, with treatment after relapse assumed to run over a 
52 week period. One general criticism of this study, and of most other modelling 
approaches, comes from the fact that short-term clinical trial data were used to underpin the 
model and were extrapolated out to suggest 12-month outcomes. This has potential flaws 
as drop-out rates can vary over time and will not necessarily remain constant. Assumed 
relative differences in drop-out rates of 20% in favour of SSRIs were much higher than 
those suggested in other studies. 
 
McFarland et al. considered the same drug comparison (paroxetine vs imipramine) over a 
one year period using a decision tree model over a 12 month period.
53
 The study took the 
prospective of a US primary care Health Maintenance Organisation (HMO). The study found 
little difference in total treatment costs per patient.  
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Stewart et al. considered the treatment of depression within a primary care context using a 
typical decision-tree model structure. The model considered treatment with TCAs 
(imipramine, amitriptyline) and SSRIs (sertraline, paroxetine).
52
 A successfully treated 
patient was given an initial 12 weeks treatment with 26 weeks follow-on maintenance 
treatment. The maximum treatment period was one year, representing patients who 
switched therapy up to a maximum of three times due to either treatment failure, relapse or 
adverse effect related drop-out. Using drop-out rates for adverse effects calculated from 
placebo-controlled studies only (19% SSRI, 27% TCA from Montgomery et al.)
3
 and efficacy 
rates from individual drug trials (55% amitriptyline, 65.1% imipramine, 70% sertraline, 70.8% 
paroxetine), the study suggested costs per successfully treated patient of £491.25 
(imipramine), £539.00 (amitriptyline), £581.46 (paroxetine) and £547.65 (sertraline). From 
these data the authors concluded that there was no indication of a clear cost-advantage 
towards SSRIs over TCAs.  
 
However, as part of the sensitivity analysis, the authors also considered total drop-out rates 
from Song et al., giving alternative cost per success results (£575.91, £632.02, £660.36, 
£584.02 respectively).
16
 This is an important comparison as Montgomery et al. is recognised 
as being more favourable towards SSRIs, due to its selection of reference TCAs.
3
  Despite 
this potential bias back towards TCAs, the sensitivity results seem to suggest an almost 
equal cost per successfully treated patient between TCAs and SSRIs.  The study can be 
criticised for a lack of robustness due to its use of efficacy data taken from an individual trial, 
rather than from a meta-analysis. 
 
Unfortunately, it also appears that the actual rates used (32.3% SSRI  and 33.2% TCA) in 
this sensitivity analysis related to total drop-out (including efficacy). Rates excluding 
elements related to efficacy should have been 25.3% and 26.4% respectively. This 
difference will have led to, at least some of, the higher cost data observed.  
 
Stewart et al. revisited their original study, factoring in both cost inflation (observed as 
positive in non-drug resource areas but negative for antidepressants) and potential sub-
therapeutic dosaging.
66
 Cost inflation alone reduced the cost gap further, although SSRIs 
still remained the more expensive treatment option (£796.97 versus £776.91). However, 
these costs were much higher than those in the previous study. The cost per extra recovery 
is quoted at £2,518 (compared with £4,417 from the previous paper). Interestingly, the 
revised analysis also considered efficacy data taken directly from the meta-analyses of 
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Song et al.
16
 and Montgomery et al.
61
 Both suggest a much smaller difference in efficacy 
drop-outs. The effect of this was to increase dramatically the cost per extra recovery. 
Factoring in adjustments for proportions of patients treated at sub-therapeutic dosaging, and 
using a placebo response (69% efficacy rate from Montgomery et al.
22
) all cost differences 
reduced to minimal levels.
18
 
 
Montgomery et al. conducted an economic analysis of nefrazodone against imipramine 
using the original model structure as presented by Jonsson and Bebbington,
21
 up-dating 
both costs and treatment patterns. Rates of adverse effects, drop-out and relapse were 
taken from a randomised trial of nefrazodone (BMS). The study considered 12-month 
treatment costs following an initial treatment period of 12 weeks, and allowed the chance of 
further relapse and re-treatment. The study found lower costs per treated patient in favour of 
nefrazodone (£218 versus £242). This advantage was also reflected in measures of cost per 
successfully treated patient (£242 versus £323). Treatment failure was estimated to cost 
£669 per patient and accounted for between 31-56% of total treatment costs. Data on drop-
out rates were suggested at 9% and 20% respectively. Drop-out due to relapse (or failure 
rate) was assumed at 9% for each treatment (the JB Model had previously assumed 25%). 
Overall treatment success rates can be inferred from the study at rates of 82.8% and 72.8% 
respectively (or overall drop-out at 17.2% and 27.2 % respectively). 
 
Einarson et al. report on a cost-effectiveness analysis conducted directly alongside the 
findings of the CCOHTA meta-analysis (previously detailed).
56
 This study considered a 
range of SSRIs and TCAs and resulted in a decision tree model representing treatment over 
six months. The results confirmed that SSRIs had a total treatment cost advantage over 
TCAs (Can$5,072 versus Can$6,199) and that venlafaxine (Can$4,770) had cost 
advantages over both. 
 
Four of the studies have actually used a cost-utility approach attempting to place values on 
health states in the form of quality adjusted life years (QALY)s.  
 
Hatziandrou et al. used a Markov model which simulated the movement of patients between 
levels of illness severity over a one year time span.
54
 The transition probabilities for the 
model were derived from an expert panel/focus group approach adopting modified Delphi 
techniques. Using a standard gamble approach they placed utility values on heath states 
which ranged from 0.785 to 0.95. Overall, the average life-time costs of treatment were 
£3,407 for SSRI treatment compared with £1,648 for episodic treatment with the dothiepin 
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(TCA). The corresponding QALY data were 14.9 and 14.1 respectively, representing a 
marginal utility gain of 0.8 QALYs. The study resulted in a cost per QALY of £2,172 for 
sertraline over dothiepin. 
 
Revicki et al. conducted a cost-utility analysis (CUA) of nefazodone, fluoxetine and 
imipramine.
60
 Using a combined decision tree and Markov model approach the study 
considered the life-time direct treatment costs of all three patient groups.
60,67
 Using similar 
techniques to Hatziandrou et al., periods spent in different health states were valued on a 
utility scale of 0 to 1, by direct cross-sectional interviewing of 70 patients. Costs and benefits 
were both discounted at 5% per annum. Patients (assumed female aged 30 years) were 
treated for a nine month period for a maximum of three episodes before long-term treatment 
was provided. From published literature, the model estimated rates of new episodes 
following recovery from the initial episode, predicting that 50% of patients have a new 
episode after one year. These rates were adapted to reflect low and high rates of recurrence 
for differing compliance groups (fully, partial and non-compliant). Around 10% of all patients 
were assumed to remain treatment-resistant irrespective of initial antidepressant treatment. 
Overall, the life-time costs (1993 Can$) were estimated at Can$50,664 nefazodone, 
Can$50,678 fluoxetine and Can$52,111 imipramine. There were also utility advantages in 
favour of both nefazodone and fluoxetine over imipramine of 13.90 QALYs, 13.79 QALYs 
and 13.18 QALYs respectively. 
 
Revicki et al. repeated a similar later analysis of nefazodone including reference to a policy 
of first-line TCA, with a later switch to SSRI fluoxetine on treatment failure.
63
 Again, 
nefazodone was shown not to be cost saving, but it was incrementally more cost effective 
when considered as a cost per QALY (US$2,555 per QALY gain). 
 
5.3.7 Conclusions 
 
The relative economic arguments of the first-line use of newer SSRI drugs has been studied 
previously by a number of recognised lead authors and has generated much debate. Whilst 
earlier economic studies tended to support an economic advantage of SSRIs, a number of 
later studies have challenged this view. Many of the contentious points relate to the 
interpretation of data drawn from previous meta-analyses and expert-panels. It is clear that 
models which attempt to include the effects of a sub-therapeutic dose (still commonly seen 
with TCAs)  produce much lower costs per successfully treated patient. 
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As yet, there appears to be no clear economic evidence of a difference between SSRIs and 
TCAs which can support fully the use of SSRIs as the first-line treatment for all patients. 
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6. OTHER ISSUES 
 
6.1 PATENT ISSUES 
 
Whilst SSRIs exist as purely branded products, the price differential between classical TCAs 
and SSRIs, typically a £20-25 difference in monthly prescribing costs, will continue to play a 
major role in influencing treatment choice.  
 
However, it is important to acknowledge that the first of the SSRIs fluoxetine (Prozac™) 
came off patent in early 2000, at about the same time as the publication of this report. This 
will obviously lead to the creation of generic versions of the drug. The precise number of 
such generic drugs, and speed of up-take, will depend on the interest of the relevant generic 
drug companies, however, it would be fair to expect such interest to be high in this case. 
The cost of generic fluoxetine is certain to be a lot less than the current list price of Prozac 
(roughly £19.38 per 28 day treatment - eBNF).
68
 The manufacturers of Prozac have 
indicated that they will still be actively marketing the drug as a branded product, along with 
additional services. What also remains unclear is exactly how this process will affect the 
remaining branded SSRIs, which will only begin to come off patent a number of years later. 
 
6.2 ONGOING RESEARCH 
 
Meta-analysis/ Systematic Review 
As part of the Cochrane systematic reviews database there is a published protocol for an 
ongoing meta-analysis which is expected to begin to report in early 2000.
69
  This provides an 
extension of earlier published reviews.
13,61
 Early feedback from the later of these reviews 
indicates very similar findings to the original report. (1999, Hotopf M. personal 
communication). 
 
Randomised Studies 
There is an ongoing randomised controlled study designed specifically to consider the cost-
effectiveness of SSRIs related to TCAs as a first-line treatment for major depression. This 
study is being conducted through the University of Southampton, Mental Health Group 
(Thompson C. personal communication) and is a response to an HTA primary research call. 
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This HTA study, called the AHEAD study (Assessing the Health Economics of 
Antidepressants), is a pragmatic RCT in representative general practice patients of three 
types of antidepressant treatment: 
 
1.  SSRIs: fluoxetine, paroxetine or sertraline (GP decides which is most appropriate for 
the patient); 
2.  Tricyclics: imipramine, amitriptyline or dothiepin (GP decides again); 
3.  Lofepramine  (No choices). 
 
Endpoints are to be assessed over one year, with monthly assessments using: self-ratings 
of depression; EuroQuoL and SF 36; use of services questionnaire. Costs will be calculated 
within an NHS frame, but data will also be collected on employment, and accidents (non-
costed). A fourth arm to the study of patients allows for a refusal of randomisation, but 
accepted follow-up. This will be used to check on the representativeness of the outcome in 
the randomised group. 
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7. CONCLUSIONS 
 
The main issue addressed by this review is the comparative effectiveness of SSRIs with 
other antidepressants, which principally means the older and newer TCAs. 
 
In clinical terms, the SSRIs appear to be as effective in improving major depression as the 
TCAs. They do not demand the same dose titration typical of the older TCAs and there are 
no issues of non-therapeutic dose formulation. They have a side-effects profile that is 
different from the older TCAs, although there is still a significant drop-out rate from side-
effects with SSRIs. The reductions in levels of sedation for SSRIs, and certain TCAs, is 
likely to play a significant role in the selection of antidepressants for certain patients. In 
particular, parents of young infants need to have full awareness at night, users of machinery 
need to be able to concentrate fully and drivers also need to ensure that medication will not 
influence their reaction times. None of the cost-effectiveness studies identified have 
attempted to consider specifically the costs and benefits of TCAs and SSRIs in such sub-
groups of patients.  
 
Although safer than the older TCAs in overdose, evidence is lacking on whether this 
represents a real advantage in reducing the risk of suicide in the depressed patient. There 
are concerns that the availability of TCAs in the home provides an increased risk of 
overdose or poisoning in not only the patient, but also in other family members. Current 
research tends to suggest that suicidal patients will find other means, and studies tend to 
show SSRIs already being used in more severe cases. 
 
Whilst there may be benefits for SSRIs when compared with the older TCAs, there is no 
such evidence of benefit compared with the newer TCA (lofepramine) although fewer 
studies have been conducted using this comparison. 
 
It is of general concern that the answers to the research questions posed are not available, 
given that it has now been 10 years since the introduction of SSRIs and there is now an 
annual NHS antidepressant expenditure of approximately £200 millon. This is largely 
because there is no mechanism, with the launch of new drugs, to set up studies to answer 
questions of improved benefit over existing agents. The costs and implications of setting up 
RCTs must be set against the considerable costs of not doing them and the opportunity 
costs therein. The HTA study previously detailed may go some way to addressing this issue. 
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Central to the above discussions has been an assumption that all antidepressant prescribing 
is for properly diagnosed major depression. It is in this area that the evidence for benefit 
exists and the cost-effectiveness arguments are considered.   
 
The symptoms present with depression can occur in response to a variety of other 
situations. There is no high level evidence for the use of antidepressants in non-major 
(minor) depression. Whilst the tenets of the Defeat Depression Campaign are supported, 
appropriate diagnosis is key to the management of depression. Diagnosing as major 
depression when only a minor depressive episode is present and then ensuring optimal 
therapeutic dosing and a full six months of drug therapy may be unnecessary expenditure 
and represent an important opportunity cost. Therefore, guidelines for the diagnosis of 
depression are advocated. 
 
Studies which looked at allowing switches of therapy between active arms, have shown 
switches to occur early with a subsequent high level of compliance. There is, therefore, an 
important argument for starting with the cheaper TCAs, and lofepramine in particular, as first 
line in the absence of significant contraindications, with a change to an SSRI if there are 
significant side-effects. The North of England guidelines advocate this approach. 
 
The key messages for purchasers are: 
 
 To formulate guidelines on the diagnosis and management of depression. 
 
 That further work is required specifically to answer the question of the cost-effectiveness 
of SSRIs over the newer TCAs. 
 
 To consider the use of the newer TCA, lofepramine, in particular unless contraindicated 
as first line drug choice. 
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APPENDIX  
 
The following table details the individual RCT data included in the meta-analysis published 
by Hotopf et al. 1997.
13
 The trials are classified by their reference antidepressant into three 
distinct groups, namely older TCAs, newer TCAs and Heterocyclics. The table demonstrates 
significant variations in drop-out both between these wide classifications and within 
classifications. 
 
Author Year TCAs and 
Related 
Drugs 
SSRI n randomised drop-outs   
    TCA SSRI TCA SSRI Odds 
ratio 
95%CI 
          
Older Tricyclics          
Altamura 1989 amitripyline fluxetine 14 14 4 2 0.47 0.08-2.71 
Amore 1989 amitripyline fluvoxamine 15 15 5 0 0.06 0.003-1.20 
Bascara 1989 amitripyline paroxetine 23 27 3 2 0.57 0.10-3.19 
Battegay 1985 amitripyline paroxetine 10 11 8 3 0.12 0.02-0.79 
Beasley 1993 amitripyline fluxetine 71 65 24 8 0.29 0.12-0.68 
Bersani 1994 amitripyline sertraline 34 34 4 3 0.75 0.17-3.30 
Bignamini & 
Rapisardi 
1992 amitripyline paroxetine 153 156 20 31 1.64 0.89-3.01 
Byrne 1989 amitripyline paroxetine 35 35 9 12 1.49 0.54-4.09 
Chouinard 1985 amitripyline fluoxetine 28 23 6 2 0.4 0.08-1.93 
Cohn 1990 amitripyline sertraline 64 121 41 79 1.06 0.56-1.99 
Fawcett 1989 amitripyline fluoxetine 19 19 10 7 0.54 0.15-1.91 
Feighner 1985 amitripyline fluoxetine 22 22 12 6 0.33 0.10-1.12 
Gasperini 1992 amitripyline fluvoxamine 26 30 1 2 1.49 0.18-12.09 
Harris 1991 amitripyline fluvoxamine 34 35 8 11 1.47 0.52-4.17 
Hutchinson 1992 amitripyline paroxetine 32 56 11 12 0.53 0.20-1.37 
Judd 1993 amitripyline fluoxetine 28 30 5 7 1.37 0.40-4.73 
Keegan 1991 amitripyline fluoxetine 22 20 3 2 0.75 0.13-4.29 
Kuhs & Rudolf 1989 amitripyline paroxetine 20 20 3 6 2.22 0.51-9.70 
Laursen 1985 amitripyline paroxetine 23 21 9 5 0.51 0.14-1.81 
Masco & Sheetz 1985 amitripyline fluxetine 21 20 5 1 0.2 0.03-1.37 
Moller 1993 amitripyline paroxetine 110 112 48 37 0.64 0.37-1.10 
Remick 1994 amitripyline fluvoxamine 17 16 6 3 0.46 0.10-2.10 
Reimherr 1990 amitripyline sertraline 149 149 63 61 0.94 0.59-1.49 
Amin 1984 imipramine fluvoxamine 113 115 64 52 1.1 0.76-1.58 
Arminen 1994 imipramine paroxetine 32 25 15 13 1.22 0.44-3.41 
Beasley 1993 imipramine fluxetine 62 56 38 33 0.91 0.55-1.51 
Bramanti 1988 imipramine fluvoxamine 30 30 1 2 1.72 0.21-13.89 
Bremner 1984 imipramine fluoxetine 20 20 3 4 1.37 0.29-6.46 
Bressa 1989 imipramine fluoxetine 15 15 1 2 1.79 0.21-15.46 
Cohn & Wilcox 1985 imipramine fluoxetine 54 54 34 19 0.33 0.15-0.72 
Cohn 1989 imipramine fluoxetine 30 30 16 13 0.68 0.25-1.85 
Dominguez 1985 imipramine fluvoxamine 30 31 11 17 2.04 0.74-5.59 
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Author Year TCAs and 
Related 
Drugs 
SSRI n randomised drop-outs   
    TCA SSRI TCA SSRI Odds 
ratio 
95%CI 
Feighner 1989 imipramine fluoxetine 57 61 28 31 1.06 0.52-2.17 
Feighner 1989 imipramine fluvoxamine 36 31 11 10 1.09 0.40-3.01 
Feighner 1993 imipramine paroxetine 237 240 127 102 0.64 0.53-0.77 
Fontaine 1991 imipramine paroxetine 50 54 23 28 1.27 0.59-2.72 
Gonella 1990 imipramine fluvoxamine 10 10 0 1 3.33 0.12-92.00 
Guelfi 1983 imipramine fluvoxamine 77 74 18 19 1.14 0.55-2.37 
Itil 1983 imipramine fluvoxamine 25 22 12 12 1.28 0.42-3.94 
Lapierre 1987 imipramine fluvoxamine 21 22 12 7 0.37 0.11-1.24 
Levine 1987 imipramine fluoxetine 30 30 2 8 4.35 0.96-19.78 
Lydiard 1989 imipramine fluvoxamine 18 18 4 1 0.21 0.03-1.51 
March 1990 imipramine fluvoxamine 18 18 3 5 1.81 0.39-83.32 
Nielsen 1991 imipramine paroxetine 15 16 9 7 0.54 0.14-2.15 
Nielsen 1993 imipramine fluoxetine 30 29 8 8 1.04 0.34-3.19 
Norton 1984 imipramine fluvoxamine 59  30 33 1.1 0.54-2.23 
Ohrberg 1992 imipramine paroxetine 77  19 13 0.66 0.30-1.44 
Shrivastava 1992 imipramine paroxetine 38  7 15 0.21 0.07-0.60 
Stark & 
Hardison 
1985 imipramine fluoxetine 186  87 87 1.01 0.67-1.52 
Stratta 1991 imipramine fluoxetine 14  5 0 0.06 0.003-1.22 
          
Newer Tricyclics        
Danish 
University Group 
1990 clomipramine paroxetine 58  19 12 0.5 0.22-1.14 
De Wilde & 
Doogan 
1982 clomipramine fluvoxamine 15  0 0   
De Wilde 1983 clomipramine fluvoxamine 21  0 0   
De Wilde 1983 clomipramine fluvoxamine 15  0 0   
Dick & Ferrero 1983 clomipramine fluvoxamine 15  3 4 1.19 0.24-5.86 
Guilibert 1989 clomipramine paroxetine 39  12 9 0.66 0.25-1.77 
Klok 1981 clomipramine fluvoxamine 18  3 5 1.81 0.39-8.32 
Link & Dunbar 1992 clomipramine paroxetine 154  28 26 0.91 0.52-1.59 
Link & Dunbar 1992 clomipramine paroxetine 56  26 27 0.94 0.46-1.94 
Link & Dunbar 1992 clomipramine paroxetine 43  9 14 1.85 0.71-4.82 
Moon 1993 clomipramine sertra 55  10 2 0.22 0.05-0.92 
Noguera 1991 clomipramine fluoxetine 60  16 13 0.77 0.34-1.76 
Robert 1989 clomipramine fluoxetine 72  24 16 0.59 0.28-1.23 
Bowden 1993 desipramine fluoxetine 30  8 5 0.62 0.18-2.1 
Nathan 1990 desipramine fluvoxamine 20  2 0 0.21 0.01-4.69 
Remick 1993 desipramine fluoxetine 20  5 2 0.29 0.06-1.47 
Roth 1990 desipramine fluvoxamine 30  9 6 0.6 0.19-1.90 
Corne & Hall 1990 dothiepin vluox 53  7 14 2.56 0.96-6.85 
Mullin 1994 dothiepin fluvoxamine 36  12 11 0.85 0.32-2.24 
Rahman 1991 dothiepin fluvoxamine 26  5 7 1.49 0.42-5.25 
South Wales 
Group 
1988 dothiepin fluoxetine 28  7 15 2.7 0.91-7.97 
Thompson 1991 dothiepin paroxetine 93  9 6 0.7 0.25-1.99 
Dunner 1992 doxepin paroxetine 135  39 45 1.22 0.73-2.04 
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Author Year TCAs and 
Related 
Drugs 
SSRI n randomised drop-outs   
    TCA SSRI TCA SSRI Odds 
ratio 
95%CI 
Feighner & 
Cohn 
1985 doxepin fluvoxamine 79  48 37 0.59 0.31-1.11 
Remick 1989 doxepin fluoxetine 37  10 13 1.39 0.53-3.67 
Tammimen & 
Lehtinen 
1989 doxepin fluoxetine 25  4 5 1.22 0.31-4.86 
Gabre 1991 nortripyline fluoxetine 102  45 39 0.79 0.45-1.36 
          
Heterocyclic antidepressants       
Dalery 1992 amineptine fluoxetine 87  14 14 1.08 0.49-2.40 
Ferreri 1989 amineptine fluoxetine 32  7 4 0.56 0.15-2.03 
Feighner 1991 bupropion fluoxetine 60  16 18 1.18 0.54-2.59 
De Jonge  1991 maprotiline fluoxetine 34  3 5 2.13 0.50-9.01 
De Jonge  1991 maprotiline fluvox 24  6 4 0.63 0.16-2.43 
Poelinger & 
Haber 
1989 maprotiline fluoxetine 69  8 12 1.47 0.57-3.76 
Besancon 1993 mianserin fluoxetine 33  9 13 1.79 0.64-4.97 
Dormon 1992 mianserin paroxetine 28  3 5 1.64 0.38-6.99 
Mertens & 
Pintens 
1988 mianserin paroxetine 31  3 3 0.85 0.18-4.06 
Moon & Jesinger 1991 mianserin fluvoxamine 31  7 6 0.83 0.25-2.72 
Muijen 1988 mianserin fluoxetine 27  13 12 0.93 0.32-2.67 
Perez & Ashford 1990 mianserin vluvoxamine 30  8 8 1 0.33-3.05 
Phanjoo 1991 mianserin fluvoxamine 25  10 9 0.85 0.28-2.60 
Teneri & Kohler 1989 nomifensine fluoxetine 20  1 5 4.55 0.66-31.18 
Debus 1988 trazodone fluoxetine 21  101 8 0.64 0.19-2.10 
Falk 1989 trazodone fluoxetine 13  9 3 0.14 0.03-0.72 
Perry 1989 trazodone fluoxetine 19  4 4 0.88 0.20-3.85 
 
 
 
  
60 
 
 
 
 
Other papers published by the Trent Institute for Health Services Research are listed 
below:- 
 
Guidance Notes for Purchasers  
 
96/01 Working Group on Acute Purchasing: The Use of DNase in   
  
£6.00 
 Cystic Fibrosis (1996) by JN Payne, S Dixon, NJ Cooper and   
 CJ McCabe.  
       
96/02 Working Group on Acute Purchasing: Tertiary Cardiology (1996)    £6.00 
 by J Tomlinson, J Sutton and CJ McCabe.  
  
96/03 Working Group on Acute Purchasing: The Use of Cochlear     £6.00 
 Implantation (1996) by Q Summerfield and J Tomlinson.  
  
96/04 Working Group on Acute Purchasing: Statin Therapy / HMG Co-A   
  Reductase Inhibitor Treatment in the Prevention of Coronary Heart 
Disease 
£6.00 
 (1996) by MD Pickin, JN Payne, IU Haq, CJ McCabe, SE Ward, PR Jackson  
 and WW Yeo.  
  
97/01 Working Group on Acute Purchasing: The Clinical and Cost-effectiveness   £10.00 
 of Computed Tomography in the Management of Transient Ischaemic   
 Attack and Stroke (1997) by A Ferguson and CJ McCabe. (Series Editor - Nick 
Payne). 
 
  
97/02 Working Group on Acute Purchasing: Prostacyclin in the Treatment of    £10.00 
 Primary Pulmonary Hypertension (1997) by TW Higenbottam, SE Ward,   
 A Brennan, CJ McCabe, RG Richards and MD Stevenson. (Series Editor - Nick 
Payne). 
 
  
97/03 Working Group on Acute Purchasing: The Use of Riluzole in the Treatment £10.00 
 of Amyotrophic Lateral Sclerosis (Motor Neurone Disease) (1997) by J Chilcott,  
 P Golightly, D Jefferson, CJ McCabe and S Walters. (Series Editor - Nick Payne). 
 
  
97/04 Working Group on Acute Purchasing: Recombinant Factor VIII Versus    £10.00 
 Plasma Derived Factor VIII in the Management of Haemophilia A: An   
 Examination of the Costs and Consequences (1997) by C Green and   
 RL Akehurst. (Series Editor - Nick Payne).  
  
97/05 Working Group on Acute Purchasing: The Use of Cisplatin and Paclitaxel £10.00 
 as a First Line Treatment in Ovarian Cancer (1997) by SM Beard, R Coleman,   
 J Radford and J Tidy. (Series Editor - Nick Payne).  
  
97/06 Working Group on Acute Purchasing: The Use of Alpha Interferon in the   
 Management of Chronic Myeloid Leukaemia (1997) by RG Richards and  
£10.00 
 CJ McCabe. (Series Editor - Nick Payne).  
  
97/07 Working Group on Acute Purchasing: Spinal Cord Stimulation in the    £10.00 
 Management of Chronic Pain (1997) by J Tomlinson, CJ McCabe and B Collett. 
(Series Editor - Nick Payne). 
 
  
97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in Adults   £5.00 
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